

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number  
**WO 2007/045979 A1**

(51) International Patent Classification:  
**A61K 31/401** (2006.01)    **A61P 37/00** (2006.01)  
**A61P 11/00** (2006.01)

(74) Common Representative: **RANBAXY LABORATORIES LIMITED**; c/o DESHMUKH Jay R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(21) International Application Number:  
PCT/IB2006/002930

(22) International Filing Date: 19 October 2006 (19.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2794/DEL/2005    19 October 2005 (19.10.2005) IN

(71) Applicant (for all designated States except US): **RANBAXY LABORATORIES LIMITED** [IN/IN]; Plot No. 90, Sector - 32, Gurgaon 122001, Haryana (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAY, Abhijit** [IN/IN]; Sector C-1, Flat No. 1408, Vasant Kunj, New Delhi 110070, Delhi (IN). **DASTIDAR, Sunanda, G.** [IN/IN]; B-138, Sarita Vihar, New Delhi 110044, Delhi (IN). **SHIRUMALLA, Rajkumar** [IN/IN]; 36A, Navyug Adarsh Apartments, Vikas Puri, New Delhi 110018, Delhi (IN). **MALHOTRA, Shivani** [IN/IN]; 28/63, IIInd Floor, West Patel Nagar, New Delhi 110008, Delhi (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2007/045979 A1

(54) Title: PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS

(57) Abstract: Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more  $\beta$ 2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

## PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS

### Technical Field of the Invention

5        Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists (“MRA”) and at least one additional active ingredient selected from one or more  $\beta$ 2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or mixtures thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or  
10      disorders are provided.

### Background of the Invention

Muscarinic receptors, members of the G Protein Coupled Receptors (GPCRs), are composed of a family of 5 receptor sub-types ( $M_1$ ,  $M_2$ ,  $M_3$ ,  $M_4$  and  $M_5$ ) and are activated by the neurotransmitter acetylcholine. These receptors are widely distributed on multiple organs  
15      and tissues and are critical to the maintenance of central and peripheral cholinergic neurotransmission. The regional distribution of these receptor sub-types in the brain and other organs has been documented. For example, the  $M_1$  subtype is located primarily in neuronal tissues such as cerebral cortex and autonomic ganglia, the  $M_2$  subtype is present primarily in the heart where it mediates cholinergically induced bradycardia, and the  $M_3$   
20      subtype is located primarily on smooth muscle and salivary glands (*Nature*, 323, p.411 (1986); *Science*, 237, p.527 (1987)).

The biological potentials of modulating muscarinic receptor subtypes by ligands in different disease conditions, such as Alzheimer’s Disease, pain, urinary disease condition, chronic obstructive pulmonary disease, and the like, are described (*Current Opinions in Chemical Biology*, 3, p. 426 (1999), as well as in *Trends in Pharmacological Sciences*, 22, p. 409 (2001) by Eglen *et al.*).

Therapeutic opportunities for muscarinic receptors in the central nervous system and elaborates on muscarinic receptor structure and function, pharmacology and their therapeutic uses are described (*J. Med. Chem.*, 43, p. 4333 (2000), by Felder *et al.*).

5 The pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists are described (*Molecules*, 6, p. 142 (2001)).

The recent developments on the role of different muscarinic receptor subtypes using different muscarinic receptor of knock out mice are described (Birdsall *et al.*, *Trends in Pharmacological Sciences*, 22, p. 215 (2001)).

10 Muscarinic agonists such as muscarine and pilocarpine and antagonists such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, making it difficult to assign specific functions to the individual receptors. Although classical muscarinic antagonists such as atropine are potent bronchodilators, their clinical utility is limited due to high incidence of both peripheral and central adverse effects such as tachycardia, blurred vision, dryness of 15 mouth, constipation, dementia, etc. Subsequent development of the quarterly derivatives of atropine such as ipratropium bromide are better tolerated than parenterally administered options, but most of these are not ideal anti-cholinergic bronchodilators, due to lack of selectivity for muscarinic receptor sub-types, resulting in dose-limiting side-effects such as thirst, nausea, mydriasis and those associated with the heart such as tachycardia mediated by 20 the M<sub>2</sub> receptor.

The pharmacology of the lower urinary tract infections are described (*Annual Review of Pharmacological Toxicol.*, 41, p. 691 (2001)). Although anti-muscarinic agents, such as oxybutynin and Tolterodine, which act non-selectively on muscarinic receptors have been used for many years to treat bladder hyperactivity, the clinical effectiveness of these agents 25 has been limited due to side effects such as dry mouth, blurred vision and constipation. Tolterodine is considered to be generally better tolerated than oxybutynin. (Steers *et al.*, in *Curr. Opin. Invest. Drugs*, 2, 268; Chapple *et al.*, in *Urology*, 55, 33; Steers et al., Adult and Pediatric Urology, ed. Gillenwater et al., pp 1220-1325, St. Louis, MO; Mosby. 3<sup>rd</sup> Edition (1996)).

Compounds having antagonistic activity against muscarinic receptors have been described in Japanese patent application Laid Open Number 92921/1994 and 135958/1994; WO 93/16048; U.S. Patent No. 3,176,019; GB 940,540; EP 0325 571; WO 98/29402; EP 0801067; EP 0388054; WO 9109013; U.S. Patent No. 5,281,601. Also, U.S. Patent Nos. 5 6,174,900, 6,130,232 and 5,948,792; WO 97/45414 describes 1,4-disubstituted piperidine derivatives; WO 98/05641 describes fluorinated, 1,4-disubstituted piperidine derivatives; and WO 93/16018 and WO96/33973 are other related references. U.S. Patent No. 5,397,800 discloses 1-azabicyclo[2.2.1]heptanes. U.S. Patent No. 5, 001,160 describes 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones. WO 01/42213 describes 10 2-biphenyl-4-piperidinyl ureas. WO 01/42212 describes carbamate derivatives. WO 01/90081 describes amino alkyl lactam. WO 02/53564 describes novel quinuclidine derivatives. WO 02/00652 describes carbamates derived from arylalkyl amines. WO 02/06241 describes 1,2,3,5-tetrahydrobenzo(c)azepin-4-one derivatives.

15 A report in *J. Med. Chem.*, 44, p. 984 (2002), describes cyclohexylmethyl piperidinyl triphenylpropioamide derivatives as selective M<sub>3</sub> antagonist discriminating against the other receptor subtypes.


However in view of the above, there remains a need for novel highly selective muscarinic receptor antagonists that can interact with distinct subtypes while avoiding the occurrence of adverse effects.

20 Summary of the Invention

In one general aspect, provided are pharmaceutical compositions comprising one or more muscarinic receptor antagonists (“MRA”) and at least one additional active ingredient selected from one or more  $\beta$ 2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents.

Suitable MRA can be one or more compounds having the structures of Formula I, II, or III, wherein:

a. Formula I is:



Formula I

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein

5    **Ar**     represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, sulphur or nitrogen, wherein

the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo

10      alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>), N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;

**R<sub>1</sub>**    represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (e.g., fluorine, chlorine, bromine and iodine);

15      **R<sub>2</sub>**    represents alkyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl ring, (C<sub>3</sub>-C<sub>7</sub>) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein


the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and

the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;

**W**    represents (CH<sub>2</sub>)<sub>p</sub>, wherein p represents 0 to 1;

- X** represents oxygen, sulphur, -NR or no atom (*i.e.*, a bond), wherein  
**R** represents hydrogen or (C<sub>1-6</sub>) alkyl;
- Y** represents CHR<sub>5</sub>CO or (CH<sub>2</sub>)<sub>q</sub>, wherein  
**R<sub>5</sub>** represents hydrogen or methyl, and  
5      **q** represents 0 to 4;
- Z** represents oxygen, sulphur, or NR<sub>10</sub>, wherein  
**R<sub>10</sub>** represents hydrogen, or C<sub>1-6</sub> alkyl;
- Q** represents (CH<sub>2</sub>)<sub>n</sub>, CHR<sub>8</sub> or CH<sub>2</sub>CHR<sub>9</sub>, wherein  
10      **n** represents 0 to 4,  
**R<sub>8</sub>** represents H, OH, C<sub>1-6</sub>, alkyl, C<sub>1-6</sub> alkenyl, or C<sub>1-6</sub> alkoxy, and  
**R<sub>9</sub>** represents H, OH, lower alkyl (C<sub>1-C<sub>4</sub></sub>) or lower alkoxy (C<sub>1-C<sub>4</sub></sub>);
- R<sub>6</sub>** and **R<sub>7</sub>** are independently selected from H, CH<sub>3</sub>, COOH, CONH<sub>2</sub>, NH<sub>2</sub> or CH<sub>2</sub>NH<sub>2</sub>; and  
**R<sub>4</sub>** represents hydrogen or C<sub>1-C<sub>15</sub></sub> saturated or unsaturated aliphatic hydrocarbon group,  
15      wherein  
1 to 6 hydrogen atoms of C<sub>1-C<sub>15</sub></sub> saturated or unsaturated aliphatic hydrocarbon  
group may be substituted with a group independently selected from halogen,  
arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein  
heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms  
independently selected nitrogen, oxygen or sulphur, and  
any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl,  
20      heteroarylalkenyl may be optionally substituted with lower alkyl (C<sub>1-C<sub>4</sub></sub>), lower perhalo alkyl (C<sub>1-C<sub>4</sub></sub>), cyano, hydroxyl, nitro, lower  
alkoxycarbonyl, halogen, lower alkoxy (C<sub>1-C<sub>4</sub></sub>), lower perhaloalkoxy  
(C<sub>1-C<sub>4</sub></sub>), unsubstituted amino, N-lower alkylamino (C<sub>1-C<sub>4</sub></sub>), or N-lower  
25      alkylamino carbonyl (C<sub>1-C<sub>4</sub></sub>);
- b. Formula II is:

6



Formula II

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein


**R<sub>1'</sub>** and **R<sub>2'</sub>** are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or phenyl, wherein

5 phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen; and

**Z'** represents oxygen or NR<sub>3</sub>, wherein

**R<sub>3</sub>** represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

10 c. Formula III is,



Formula III

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein

**R<sub>1''</sub>** and **R<sub>2''</sub>** are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub>

15 cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen;

**R<sub>3'</sub>** represents C<sub>1</sub>-C<sub>6</sub> alkyl, wherein

1-3 hydrogen atom(s) may be substituted with a group independently selected from C<sub>5</sub>-C<sub>7</sub> cycloalkyl, 1,3-dioxo-1,3-dihydro-isoindolyl or phenyl, wherein

phenyl is optionally substituted with one or more groups independently selected C<sub>1</sub>-C<sub>4</sub> alkyl or halogen; and

**Z** represents oxygen or NR<sub>4</sub>', wherein

**R**<sub>4</sub>' represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

5 Pharmaceutical compositions described herein can include one or more of the following compounds of Formula I, II and Formula III, for example:

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 1),

10 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 2),

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 3),

(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 4),

15 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 5)

(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 6),

20 (1a,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 7),

(1a,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 8),

(1a,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 9),

25 (1a,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 10),

- (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 11),
- (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 12),
- 5 (1a,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 13),
- (1a,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 14),
- 10 (1a,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 15),
- (1a,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 16),
- (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 17),
- 15 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 18),
- (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 19),
- 20 (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 20),
- (1a,5a,6a)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 21),
- (1a,5a,6a)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 22),
- 25 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 23),

- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 24),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 25),
- 5 (1a,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 26),
- (1a,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 27),
- 10 (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 28),
- (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 29),
- (2R) (+)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 30),
- 15 (2R) (+)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 31),
- (2S)-(-)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 32),
- (2S)-(-)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 33),
- 20 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt (Compound No. 34),
- (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 35),
- 25 (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 36),

10

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound No. 37),

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopropyl-2-phenyl acetamide (Compound No. 38),

5 (1a,5a,6a)-N-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 39),

(1a,5a,6a)-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 40),

10 (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L-(+)-tartrate salt (Compound No. 41),

(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2 diphenyl acetate L(+)-tartrate salt (Compound No. 42),

(1a,5a,6a)- [3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)-tartrate salt (Compound No. 43),

15 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt (Compound No. 44),

(1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 45),

20 (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 46),

(1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 47),

(1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide(Compound No. 48),

25 (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 49),

11

- (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 50),
- (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 51),
- 5 (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 52),
- (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 53),
- (1a,5a,6a)-N-[3-(3-methyl-2-but enyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-10 hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 54),
- (1a,5a,6a)-N-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 55),
- (1a,5a,6a)-N-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 56),
- 15 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 57),
- (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 58),
- (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-20 cyclopentyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 59),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide .hydrochloride salt (Compound No. 60),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L(-) malic acid salt (Compound No. 61),
- 25 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. maleate salt (Compound No. 62),

12

(2R,2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 63),

(2R,2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 64),

5 (2R)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 65),

(2R)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 66),

10 (2S)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 67),

(2S)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 68),

(2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 69),

15 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide (Compound No. 70),

(2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound No. 71),

20 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide tartarate salt (Compound No. 72),

(2R) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound No. 73),

(2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide (Compound No. 74),

25 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound No. 75),

13

- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound No. 76),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 77),
- 5 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 78),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 79),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-N-methyl-2-phenyl acetamide (Compound No. 80),
- 10 N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 81),
- N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide tartarate salt (Compound No. 82),
- 15 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide (Compound No. 83),
- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide hydrochloride salt (Compound No. 84),
- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenyl acetamide (Compound No. 85),
- 20 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetic acid (Compound No. 86),
- (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 87),
- 25 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 88),

14

(2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 89),

(2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 90),

5 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 91),

(2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetamide (Compound No. 92),

10 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 93),

(2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(m-methylphenyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 94),

(2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-phenylacetamide (Compound No. 95),

15 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-phenylacetamide (Compound No. 96),

(2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 97),

20 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 98),

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N- {-[4-(1,3-dioxo-1, 3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo[3.1.0] hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 99),

(2R) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopent-1-enyl-2-phenylacetamide (Compound No. 100),

15

- (2R, 2S) (1a, 5a, 6a)-N-(3-Isopropyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 101),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Diphenylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 102),
- 5 (2R, 2S) (1a, 5a, 6a)-N-(3-sec-butyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 103),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-pentyl)-2-phenylacetamide (Compound No. 104),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-
- 10 cyclohexyl-2-(4-methoxyphenyl) acetamide (Compound No. 105),
- (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-(N-ethyl)-2-phenylacetamide (Compound No. 106),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-ethyl)-2-phenylacetamide (Compound No. 107),
- 15 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-(N-ethyl)-2-phenylacetamide (Compound No. 108),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-pentyl)-(N-methyl)-2-phenylacetamide (Compound No. 109),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(sec-  
20 butyl)-(N-methyl)-2-phenylacetamide (Compound No. 110),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-(N-methyl)-2-phenylacetamide (Compound No. 111),
- (2R, 2S) (1a, 5a, 6a)-N-[3-(4-tert-butyl-benzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 112),
- 25 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohex-2-enyl-2-phenylacetamide (Compound No. 113),

16

- (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 114),
- (2R, 2S) (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 115),
- 5 (2R, 2S) (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 116),
- (1a, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 117),
- 10 (1a, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 118),
- (2R, 2S) (1a, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 119),
- (2R, 2S) (1a, 5a, 6a)-N-[2-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 120),
- 15 (1a, 5a, 6a)-N-[3-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 121),
- (2R, 2S) (1a, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 122),
- 20 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-2-phenylacetamide (Compound No. 123),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 124),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 125),
- 25 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenyl acetic acid ester (Compound No. 126),

17

- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-(N-methyl)-2-phenylacetamide (Compound No. 127),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenylacetamide (Compound No. 128),
- 5 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 129),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenyl acetic acid ester (Compound No. 130),
- 10 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester (Compound No. 131),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester tartarate salt (Compound No. 132),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide (Compound No. 133),
- 15 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide tartarate salt (Compound No. 134),
- (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2,2-di(4-fluorophenyl)acetic acid ester (Compound No. 135),
- 20 (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-di(4-fluorophenyl)-acetamide (Compound No. 136),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclobutyl-2-phenyl acetic acid ester (Compound No. 137),
- (2R, 2S) (1a, 5a, 6a)-N-(3-cyclohexylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 138),
- 25 (2R) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-methyl)-2-phenylacetamide (Compound No. 139),

18

(2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-(4-methylphenyl) acetamide (Compound No. 140),

(2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-2-(4-methylphenyl) acetic acid ester (Compound No. 141),

5 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-2-phenyl acetic acid ester (Compound No. 142),

(2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-methyl-2-phenyl acetamide (Compound No. 143),

(2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-

10 2-phenyl acetic acid ester (Compound No. 144),

(1a, 5a, 6a)-N-(3-methyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-phenyl-(N-methyl)-2-phenylacetamide (Compound No. 145),

(1a, 5a, 6a)-N- (3-benzyl-3-azabicyclo [3.1.0] hex-6-yl-methyl]-2-hydroxy-2, 2-di (3-methylphenyl) acetamide (Compound No. 146),

15 (2R, 2S) (1a, 5a; 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-(3-pentyl)-2-phenyl acetic acid ester (Compound No. 147),

(2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-(N-methyl)-2-phenylacetamide (Compound No. 148),

N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0.]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl)

20 phenyl acetamide hydrochloride (Compound No. 149), or

Tartarate salt of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)2-thienylacetate (Compound No. 150).

In another general aspect there is provided methods of treating or preventing autoimmune, inflammatory, or allergic diseases or disorders, which comprises administering

25 to a mammal in need thereof a pharmaceutical composition comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more  $\beta$ 2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors,

19


corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. Suitable MRA are one or more compounds having the structures of Formula I, II, or III as defined above.

Detailed Description of the Invention

5       In one aspect, there is provided pharmaceutical compositions comprising one or more muscarinic receptor antagonists (“MRA”) and at least one additional active ingredients selected from one or more  $\beta$ 2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents

10      MRA described herein include compounds having the structures of Formula I, II, or III, wherein

Formula I is:



Formula I

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, 15 diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein

**Ar**     represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, sulphur or nitrogen, wherein

the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>), N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;

20

**R<sub>1</sub>**     represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (*e.g.*, fluorine, chlorine, bromine and iodine);

20

**R<sub>2</sub>** represents alkyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl ring, (C<sub>3</sub>-C<sub>7</sub>) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein

the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and

5 the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;

10 **W** represents (CH<sub>2</sub>)<sub>p</sub>, wherein p represents 0 to 1;

**X** represents oxygen, sulphur, -NR or no atom (*i.e.*, a bond), wherein

**R** represents hydrogen or (C<sub>1</sub>-<sub>6</sub>) alkyl;

**Y** represents CHR<sub>5</sub>CO or (CH<sub>2</sub>)<sub>q</sub>, wherein

15 **R<sub>5</sub>** represents hydrogen or methyl, and

**q** represents 0 to 4;

**Z** represents oxygen, sulphur, or NR<sub>10</sub>, wherein

**R<sub>10</sub>** represents hydrogen, or C<sub>1</sub>-<sub>6</sub> alkyl;

**Q** represents (CH<sub>2</sub>)<sub>n</sub>, CHR<sub>8</sub> or CH<sub>2</sub>CHR<sub>9</sub>, wherein

20 **n** represents 0 to 4,

**R<sub>8</sub>** represents H, OH, C<sub>1</sub>-<sub>6</sub>, alkyl, C<sub>1</sub>-<sub>6</sub> alkenyl, or C<sub>1</sub>-<sub>6</sub> alkoxy, and

**R<sub>9</sub>** represents H, OH, lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or lower alkoxy (C<sub>1</sub>-C<sub>4</sub>);

**R<sub>6</sub>** and **R<sub>7</sub>** are independently selected from H, CH<sub>3</sub>, COOH, CONH<sub>2</sub>, NH<sub>2</sub> or CH<sub>2</sub>NH<sub>2</sub>; and

25 **R<sub>4</sub>** represents hydrogen or C<sub>1</sub>-C<sub>15</sub> saturated or unsaturated aliphatic hydrocarbon group, wherein


1 to 6 hydrogen atoms of C<sub>1</sub>-C<sub>15</sub> saturated or unsaturated aliphatic hydrocarbon group may be substituted with a group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein

21

heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms independently selected nitrogen, oxygen or sulphur, and any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl, heteroarylalkenyl may be optionally substituted with lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxyl, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhaloalkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkylamino (C<sub>1</sub>-C<sub>4</sub>), or N-lower alkylamino carbonyl (C<sub>1</sub>-C<sub>4</sub>);

5

b. Formula II is:



Formula II

10

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein


R<sub>1</sub>' and R<sub>2</sub>' are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen; and

Z' represents oxygen or NR<sub>3</sub>, wherein

R<sub>3</sub> represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

15

c. Formula III is,



Formula III

20

22

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein

**R<sub>1</sub>"** and **R<sub>2</sub>"** are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen;

5 groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halo gen;

$\mathbf{R}_3'$  represents C<sub>1</sub>-C<sub>6</sub> alkyl, wherein

1-3 hydrogen atom(s) may be substituted with a group independently selected from C<sub>5</sub>-C<sub>7</sub> cycloalkyl, 1,3-dioxo-1,3-dihydro-isoindolyl or phenyl, wherein

phenyl is optionally substituted with one or more groups independently

selected C<sub>1</sub>-C<sub>4</sub> alkyl or halogen; and

**Z** represents oxygen or  $\text{NR}_4'$ , wherein

$\mathbf{R}_4'$  represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

The pharmaceutical compositions of each of the above aspects can include one or more of the following embodiments. For example, the one or more compounds of Formula I, II and Formula III can be selected from:

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 1),

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 2).

(1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 3).

(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate  
(Compound No. 4),

(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 5),

23

- (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 6),
- (1a,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 7),
- 5 (1a,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 8),
- (1a,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 9),
- (1a,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 10),
- 10 (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 11),
- (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 12),
- 15 (1a,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 13),
- (1a,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 14),
- (1a,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
- 20 hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 15),
- (1a,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 16),
- (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 17),
- 25 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 18),

24

- (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 19),
- (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 20),
- 5 (1a,5a,6a)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 21),
- (1a,5a,6a)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 22),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2,2-
- 10 diphenyl acetamide (Compound No. 23),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 24),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 25),
- 15 (1a,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 26),
- (1a,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 27),
- (2R)-(+) - (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
- 20 cyclohexyl-2-phenyl acetamide (Compound No. 28),
- (2R)-(+) - (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 29),
- (2R) (+)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 30),
- 25 (2R) (+)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate(Compound No. 31),

25

- (2S)-(-)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 32),
- (2S)-(-)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 33),
- 5 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt (Compound No. 34),
- (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 35),
- 10 (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 36),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound No. 37),
- 15 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopropyl-2-phenyl acetamide (Compound No. 38),
- (1a,5a,6a)-N-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 39),
- (1a,5a,6a)-[3-(3,4-methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 40),
- 20 (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L-(+)-tartrate salt (Compound No. 41),
- (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2 diphenyl acetate L(+)tartrate salt (Compound No. 42),
- (1a,5a,6a)- [3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)tartrate salt (Compound No. 43),
- 5 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)tartrate salt (Compound No. 44),

26

- (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 45),
- (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 46),
- 5 (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 47),
- (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 48),
- (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-10 2,2-diphenyl acetamide (Compound No. 49),
- (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 50),
- (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 51),
- 15 (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 52),
- (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 53),
- (1a,5a,6a)-N-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-20 hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 54),
- (1a,5a,6a)-N-[3-(3,4-methylenedioxypyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 55),
- (1a,5a,6a)-N-[3-(3,4-methylenedioxypyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 56),
- 25 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 57),

27

- (1a,5a,6a)-[3-(2-(3,4-methylenedioxypyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 58),
- (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 59),
- 5 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide .hydrochloride salt (Compound No. 60),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide. L(-) malic acid salt (Compound No. 61),
- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
- 10 cyclopentyl-2-phenyl acetamide. maleate salt (Compound No. 62),
- (2R,2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 63),
- (2R,2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 64),
- 15 (2R)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 65),
- (2R)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 66),
- (2S)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-
- 20 phenyl acetamide (Compound No. 67),
- (2S)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 68),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 69),
- !5 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cycloheptyl-2-phenyl acetamide (Compound No. 70),

28

- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide (Compound No. 71),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclobutyl-2-phenyl acetamide tartarate salt (Compound No. 72),
- 5 (2R) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound No. 73),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3-fluorocyclopentyl)-2-phenyl acetamide (Compound No. 74),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-10 difluorocyclopentyl)-2-phenyl acetamide (Compound No. 75),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound No. 76),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetate (Compound No. 77),
- 15 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 78),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 79),
- (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-N-20 methyl-2-phenyl acetamide (Compound No. 80),
- N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 81),
- N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenylacetamide tartarate salt (Compound No. 82),
- !5 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide (Compound No. 83),

29

- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetamide hydrochloride salt (Compound No. 84),
- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenyl acetamide (Compound No. 85),
- 5 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetic acid (Compound No. 86),
- (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 87),
- 10 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 88),
- (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 89),
- (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 90),
- 15 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 91),
- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetamide (Compound No. 92),
- (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 93),
- 20 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(m-methylphenyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 94),
- (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-phenylacetamide (Compound No. 95),
- 5 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-phenylacetamide (Compound No. 96),

30

- (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 97),
- (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 98),
- 5 (2R, 2S) (1a, 5a, 6a)-N- {-[4-(1,3-dioxo-1, 3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo [3.1.0] hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 99),
- (2R) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopent-1-enyl-2-phenylacetamide (Compound No. 100),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Isopropyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-10 cyclopentyl-2-phenylacetamide (Compound No. 101),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Diphenylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 102),
- (2R, 2S) (1a, 5a, 6a)-N-(3-sec-butyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 103),
- 15 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-pentyl)-2-phenylacetamide (Compound No. 104),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-2-(4-methoxyphenyl) acetamide (Compound No. 105),
- (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-(N-ethyl)-20 2-phenylacetamide (Compound No. 106),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-ethyl)-2-phenylacetamide (Compound No. 107),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohexyl-(N-ethyl)-2-phenylacetamide (Compound No. 108),
- 15 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-pentyl)-(N-methyl)-2-phenylacetamide (Compound No. 109),

- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(sec-butyl)-(N-methyl)-2-phenylacetamide (Compound No. 110),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-(N-methyl)-2-phenylacetamide (Compound No. 111),
- 5 (2R, 2S) (1a, 5a, 6a)-N-[3-(4-tert-butyl-benzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 112),
- (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohex-2-enyl-2-phenylacetamide (Compound No. 113),
- (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 114),
- 10 (2R, 2S) (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 115),
- (2R, 2S) (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 116),
- 15 (1a, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 117),
- (1a, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 118),
- (2R, 2S) (1a, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 119),
- 20 (2R, 2S) (1a, 5a, 6a)-N-[2-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 120),
- (1a, 5a, 6a)-N-[3-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 121),
- 25 (2R, 2S) (1a, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 122),

32

- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-2-phenylacetamide (Compound No. 123),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 124),
- 5 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 125),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenyl acetic acid ester (Compound No. 126),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-(N-methyl)-2-phenylacetamide (Compound No. 127),
- 10 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenylacetamide (Compound No. 128),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 129),
- 15 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenyl acetic acid ester (Compound No. 130),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetic acid ester (Compound No. 131),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-
- 20 cyclopentyl-2-(3-methylphenyl) acetic acid ester tartarate salt (Compound No. 132),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide (Compound No. 133),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide tartarate salt (Compound No. 134),
- 25 (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2,2-di(4-fluorophenyl)acetic acid ester (Compound No. 135),

33

- (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-di(4-fluorophenyl)-acetamide (Compound No. 136),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclobutyl-2-phenyl acetic acid ester (Compound No. 137),
- 5 (2R, 2S) (1a, 5a, 6a)-N-(3-cyclohexylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 138),
- (2R) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-(N-methyl)-2-phenylacetamide (Compound No. 139),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-
- 10 cyclopentyl-2-(4-methylphenyl) acetamide (Compound No. 140),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-2-(4-methylphenyl) acetic acid ester (Compound No. 141),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-2-
- 15 phenyl acetic acid ester (Compound No. 142),
- (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-methyl-2-
- 20 phenyl acetamide (Compound No. 143),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-2-phenyl acetic acid ester (Compound No. 144),
- (1a, 5a, 6a)-N-(3-methyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-phenyl-(N-
- 25 methyl)-2-phenylacetamide (Compound No. 145),
- (1a, 5a, 6a)-N- (3-benzyl-3-azabicyclo [3.1.0] hex-6-yl-methyl]-2-hydroxy-2, 2-di (3-methylphenyl) acetamide (Compound No. 146),
- (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-(3-pentyl)-2-phenyl acetic acid ester (Compound No. 147),
- 25 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-(N-methyl)-2-phenylacetamide (Compound No. 148),

N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide hydrochloride (Compound No. 149), or

Tartarate salt of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)2-thienylacetate (Compound No. 150).

5 Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or III described herein, a therapeutically effective amount of one or more  $\beta$ 2-agonists, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more corticosteroids, one or more p38 MAP kinase  
10 inhibitors, one or more PDE-IV inhibitors or combinations thereof.

Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or II described herein, a therapeutically effective amount of one or more corticosteroids, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a  
15 therapeutically effective amount of one or more  $\beta$ 2-agonists, one or more p38 MAP kinase inhibitors, one or more PDE-IV inhibitors or combinations thereof.

Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or III described herein, a therapeutically effective amount of one or more p38 MAP kinase inhibitors, and one or more  
20 pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more corticosteroids, one or more  $\beta$ 2-agonists, one or more PDE-IV inhibitors or combinations thereof.

Also provided are pharmaceutical dosage forms comprising a therapeutically effective amount of one or more compounds of Formula I, II, or III described herein, a therapeutically effective amount of one or more PDE-IV inhibitors, and one or more pharmaceutically acceptable carriers, excipients or diluents. Such pharmaceutical dosage form may also include a therapeutically effective amount of one or more corticosteroids, one or more  $\beta$ 2-agonists, one or more p38 MAP kinase inhibitors or combinations thereof.

Suitable  $\beta_2$ -agonists as described herein may be any  $\beta_2$ -agonist described in the art or subsequently discovered. For example,  $\beta_2$ -agonists may include, but are not limited to, one or more compounds described in U.S. Patent Nos. 3,705,233; 3,644,353; 3,642,896; 3,700,681; 4,579,985; 3,994,974; 3,937,838; 4,419,364; 5,126,375; 5,243,076; 4,992,474; and 4,011,258,

5 each of which are incorporated herein by reference.

Examples of suitable  $\beta_2$ -agonists include one or more of albuterol, salbutamol, biltolterol, pirbuterol, levosalbutamol, tulobuterol, terbutaline, bambuterol, metaproterenol, fenoterol, salmeterol, carmoterol, arformoterol, formoterol, and their pharmaceutically acceptable salts or solvates thereof or mixtures thereof.

10 Suitable corticosteroids as described herein may be any corticosteroid described in the art or subsequently discovered. For example, corticosteroids may include, but are not limited to, one or more compounds described in U.S. Patent Nos. 3,312,590; 3,983,233; 3,929,768; 3,721,687; 3,436,389; 3,506,694; 3,639,434; 3,992,534; 3,928,326; 3,980,778; 3,780,177; 3,652,554; 3,947,478; 4,076,708; 4,124,707; 4,158,055; 4,298,604; 4,335,121; 4,081,541;

15 4,226,862; 4,290,962; 4,587,236; 4,472,392; 4,472,393; 4,242,334; 4,014,909; 4,098,803; 4,619,921; 5,482,934; 5,837,699; 5,889,015; 5,278,156; 5,015,746; 5,976,573; 6,337,324; 6,057,307; 6,723,713; 6,127,353; and 6,180,781, each of which are incorporated herein by reference.

Examples of suitable corticosteroids include one or more of alclometasone, amcinonide, amelometasone, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, cloticasone, cyclomethasone, deflazacort, deprodone, dexamethasone, diflunisal, difluprednate, fluticasone, flunisolide, halometasone, halopredone, hydrocortisone, hydrocortisone, methylprednisolone, mometasone, prednicarbate, prednisolone, rimexolone, tixocortal, triamcinolone, ulobetasol, and pharmaceutically acceptable salts, solvates thereof, or mixtures thereof.

25 Suitable PDE-IV inhibitors may be any PDE-IV inhibitors described in the art or subsequently discovered. For example, PDE-IV inhibitors may include, but are not limited to, one or more compounds disclosed in WO 2005/021515, co-pending Indian Patent Application No. 303/DEL/2005; enprofylline, roflumilast, ariflo, Bay-198004, CP-325366 (WO 96/39408),

BY343 (WO 98/21208), D-4396 (Sch-351591) (WO 00/26208), V-11294A, Z-15370 (WO 00/05218), and AWD-12-281 (WO 99/55696).

Other examples of PDE-IV inhibitors include compounds selected from:

- 3-[3-{[(3*S*)-1-Benzylpyrrolidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 1a),  
5  
3-[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]propan-1-ol (Compound No. 2a),  
[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetonitrile (Compound No. 3a),  
10 4-[(5*S* or 5*R*)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 4a),  
4-[(5*R* or 5*S*)-1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 5a),  
5-[(5*S* or 5*R*)-1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 6a),  
15 (5*S* or 5*R*)-3-(3,4-Dimethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 7a),  
(5*R* or 5*S*)-3-(3,4-Dimethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 8a),  
2-*(Benzyl*oxy)-4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 9a),  
20 2-[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]ethanol (Compound No. 10a),  
3-[4-(Difluoromethoxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 11a),  
3-[3-(Cyclohexyloxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
25 (Compound No. 12a),  
(5*R* or 5*S*)-3-[4-(Difluoromethoxy)-3-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 13a),

- (5S or 5R)-3-[4-(Difluoromethoxy)-3-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 14a),
- Ethyl [2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetate  
(Compound No. 15a),
- 5 3-[4-(Difluoromethoxy)-3-(2-morpholin-4-yethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-  
ene (Compound No. 16a),
- 2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl  
cyclohexanecarboxylate (Compound No. 17a),
- 5-[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pentanoic acid
- 10 (Compound No. 18a),
- 3-[3-(2,2,2-Trifluoroethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 19a),
- 3-[3-(Cyclopentylmethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 20a),
- 15 *N*-cyclopropyl-2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-  
yl)phenoxy]acetamide (Compound No. 21a),
- 2-[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetamide  
(Compound No. 22a),
- 2-[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]-*N*-  
20 methylacetamide (Compound No. 23a),
- 3-[3-(Cyclopentyloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 24a),
- 2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl  
cyclopropanecarboxylate (Compound No. 25a),
- 25 2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl morpholine-4-  
carboxylate (Compound No. 26a),

- 2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl benzoate (Compound No. 27a),  
5-[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy] pentanamide (Compound No. 28a),  
5 3-[3-Propoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 29a),  
3-[3-Isopropoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 30a),  
10 3-[3-(Cyclopropylmethoxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 31a),  
3-[3-(2,3-Dihydro-1*H*-inden-2-yloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 32a),  
5-(1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenol (Compound No. 33a),  
15 3-[3-Methoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 34a),  
3-[3-Ethoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 35a),  
3-[3-Butoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene 10019955  
20 (Compound No. 36a),  
3-[3-(Cyclohexylmethoxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 37a),  
3-{[2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl} benzonitrile (Compound No. 38a),  
25 2-{2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]ethyl}-1*H*-isoindole-1,3(2*H*)-dione (Compound No. 39a),

- 3-[3-(Cyclohexyloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 40a),  
Ethyl [5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy) phenoxy]acetate  
(Compound No. 41a),  
5 3-[3-(Cyclohexylmethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 42a),  
*Tert*-butyl [2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetate  
(Compound No. 43a),  
N-cyclopropyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)  
10 phenoxy]acetamide (Compound No. 44a),  
2-(Cyclopentyloxy)-4-[(5*R* or 5*S*)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound  
No. 45a),  
2-(Cyclopentyloxy)-4-[(5*S* or 5*R*)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound  
No. 46a),  
15 N-benzyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)  
phenoxy]acetamide (Compound No. 47a),  
N-Cyclopentyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)  
phenoxy]acetamide (Compound No. 48a),  
Tert-butyl 4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]  
20 piperidine-1-carboxylate (Compound No. 49a),  
Hydrochloride salt of 3-[4-(difluoromethoxy)-3-(piperidin-4-yloxy)phenyl]-1,7-dioxa-2-  
azaspiro[4.4]non-2-ene (Compound No. 50a),  
3-{3-[(1-Acetyl[4.4]non-2-ene (Compound No. 51a),  
25 Tert-butyl (3*S*)-3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-  
yl)phenoxy]pyrrolidine-1-carboxylate (Compound No. 52a),  
Tert-butyl (3*R*)-3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-  
yl)phenoxy]pyrrolidine-1-carboxylate (Compound No. 53a),

40

- Tert-butyl 3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidine-1-carboxylate (Compound No. 54a),
- Tert-butyl (2S)-2-{[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl}pyrrolidine-1-carboxylate (Compound No. 55a),
- 5 (5R or 5S)-3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 56a),
- (5S or 5R)-3-(3-isopropoxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 57a),
- 10 (5S or 5R)-3-[3-(Cyclopropylmethoxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 58a),
- 2-(Cyclopropylmethoxy)-4-[(5S or 5R)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 59a),
- 4-[(5S or 5R)-1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-isopropoxyphenol (Compound No. 60a),
- 15 (5S or 5R)-3-[3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 61a),
- (5S or 5R)-3-[3-(Cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 62a),
- 20 (5S or 5R)-3-[4-(difluoromethoxy)-3-isopropoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 63a),
- (5R or 5S)-3-[4-(difluoromethoxy)-3-isopropoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 64a),
- 2-(Cyclopropylmethoxy)-4-[(5R or 5S)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 65a),
- 25 4-[(5R or 5S)-1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-isopropoxyphenol (Compound No. 66a),

41

(5R or 5S)-3-[3-(Cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 67a),

(5R or 5S)-3-[4-(difluoromethoxy)-3-isopropoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 68a),

5 Hydrochloride salt of 3-{4-(difluoromethoxy)-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 69a),

Hydrochloride salt of 3-{4-(difluoromethoxy)-3-[(2S)-pyrrolidin-2-ylmethoxy]phenyl}-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 70a),

10 Hydrochloride salt of 3-{4-(difluoromethoxy)-3-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 71a),

3-[4-(Difluoromethoxy)-3-{[(2R)-1-propionylpyrrolidin-2-yl]methoxy}phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 72a),

3-[3-{[(2S)-1-acetylpyrrolidin-2-yl]methoxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 73a),

15 3-[3-{[(3S)-1-benzylpyrrolidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 74a),

3-[4-(Difluoromethoxy)-3-{[(3S)-1-propionylpyrrolidin-3-yl]oxy}phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 75a),

20 (5S or 5R)-3-[3-(Benzylxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 76a),

2-(Benzylxy)-4-[(5S or 5R)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 77a),

(5S or 5R)-3-[3-(Benzylxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 78a),

25 3-{4-(Difluoromethoxy)-3-[(1-propionylpiperidin-4-yl)oxy]phenyl}-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 79a),

42

- 3-[4-(Difluoromethoxy)-3-{{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 80a),
- 3-[3-{{[1-(Cyclopropylcarbonyl)piperidin-4-yl]oxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 81a),
- 5 3-[3-{{[1-(Cyclopentylcarbonyl)piperidin-4-yl]oxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 82a),
- 3-[4-(Difluoromethoxy)-3-{{[1-[(trifluoromethyl)sulfonyl]piperidin-4-yl]oxy}phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 83a),
- 10 3-[3-[(1-Acetyl piperidin-3-yl)oxy]-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 84a),
- 3-[4-(Difluoromethoxy)-3-[(1-propionylpiperidin-3-yl)oxy]phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 85a),
- 3-[4-(Difluoromethoxy)-3-{{[1-(4-fluorobenzoyl)piperidin-3-yl]oxy}phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 86a),
- 15 3-[3-{{[1-(Cyclopropylcarbonyl)piperidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 87a),
- 3-[3-{{[1-(Cyclopentylcarbonyl)piperidin-3-yl]oxy}-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 88a),
- 20 3-[4-(Difluoromethoxy)-3-{{[1-(ethylsulfonyl)piperidin-3-yl]oxy}phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 89a),
- 3-[3-(Benzyl oxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 90a),
- 2-(Difluoromethoxy)-5-[(5*S* or 5*R*)-1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl]phenol (Compound No. 91a),
- 25 5-[(5*R* or 5*S*)-1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl]-2-methoxyphenol (Compound No. 92a)

and any pharmaceutically acceptable acid addition salts thereof.

Other suitable PDE-IV inhibitors (disclosed in co-pending Indian Patent Application No. 303/DEL/2005) include, for example:

3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-en-6-ol

5 (Compound No. 1aa),

3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-*N*-(4-fluorophenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide (Compound No. 2aa),

3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-(tetrahydrofuran-3-ylcarbonyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 3aa),

10 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-*N,N*-dimethyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-sulfonamide (Compound No. 4aa),

*N*-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide (Compound No. 5aa),

2-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.4]non-2-en-7-

15 yl}acetamide (Compound No. 6aa),

Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-prolyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 7aa),

3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-morpholin-4-yl-ethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 8aa),

20 *N*-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide (Compound No. 9aa),

3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-(methylsulfonyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 10aa),

3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.4]non-2-ene (Compound No. 11aa),

3-[3,4-bis(2-morpholin-4-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 12aa),

44

- 3-(3,4-diisopropoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 13aa),  
3-[3-methoxy-4-(2-morpholin-4-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 14aa),  
3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-en-8-one  
5 (Compound No. 15aa),  
3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-en-8-ol  
(Compound No. 16aa),  
3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-isopropyl-1-oxa-2,7-diazaspiro [4.4] non-2-ene  
(Compound No. 17aa),  
10 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-7-(cyclopropylcarbonyl)-1-oxa-2,7-  
diazaspiro[4.4]non-2-ene (Compound No. 18aa),  
*N*-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-  
carboxamide (Compound No. 19aa),  
7-acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.4]non-2-ene  
15 (Compound No. 20aa),  
*Tert*-butyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.5]dec-2-ene-7-  
carboxylate (Compound No. 21aa),  
*N*-butyl-*N'*-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-  
yl}urea (Compound No. 22aa),  
20 *N*-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl}-*N'*-(2-  
methoxyphenyl)urea (Compound No. 23aa),  
3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol (Compound No.  
24  
Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.5]dec-  
25 -ene (Compound No. 25aa),

45

- 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-one (Compound No. 26aa),
- 3-[3,4-bis(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 27aa),
- 5 3-[3,4-Bis(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 28aa),
- 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-en-4-ol (Compound No. 29aa),
- 10 (R)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 30aa),
- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(cyclopropylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 31aa),
- N*-Benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide (Compound No. 32aa),
- 15 3-[3,4-Bis(benzyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 33aa),
- 4-(1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)benzene-1,2-diol (Compound No. 34aa),
- 7-Amino-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.4]non-2-en-6-one (Compound No. 35aa),
- 20 Ethyl 8-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-4-carboxylate (Compound No. 36aa),
- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylic acid (Compound no. 37aa),
- 8-Benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 38aa),
- 25 Ethyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylate (Compound No. 39aa),

46

- 3-[3-(Difluoromethoxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 40aa),  
2-(Difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 41aa),  
5 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.4]non-2-en-6-one  
(Compound No. 42aa),  
3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,6a-dimethyl-3aH-cyclopenta[d]isoxazole-  
4,6(5H,6aH)-dione (Compound No. 43aa),  
3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d]isoxazole  
10 (Compound No. 44aa),  
3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-6,6a-dihydrofuro[3,4-d]isoxazol-4(3aH)-one  
(Compound No. 45aa),  
Tert-butyl [(3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-  
yl]amino)carbonyl]carbamate (Compound No. 46aa),  
15 N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-  
yl}cyclopentanecarboxamide (Compound No. 47aa),  
8-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene  
(Compound No. 48aa),  
20 8-(Cyclopentylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-  
diazaspiro[4.5]dec-2-ene (Compound No. 49aa),  
3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-piperidin-1-ylethyl)-1-oxa-2,8-  
diazaspiro[4.5]dec-2-ene (Compound No. 50aa),  
3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
51aa),  
25 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1,8-dioxa-2-azaspiro[4.5]dec-2-ene (Compound  
No. 52aa),

47

- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a*H*-cyclopenta[*d*]isoxazole-4,6(5*H*,6*aH*)-dione  
(Compound No. 53aa),
- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-ethyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene  
(Compound No. 54aa),
- 5 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-vinyl-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol  
(Compound No. 55aa),
- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,4,5,6,7,7a-hexahydro-1,2-benzisoxazole  
(Compound No. 56aa),
- 10 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-4,5,6,6a-tetrahydro-3a*H*-cyclopenta[*d*]isoxazole  
(Compound No. 57aa),
- N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-  
yl} methanesulfonamide (Compound No. 58aa),
- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-methyl-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol  
(Compound No. 59aa),
- 15 3-[3-(Allyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
60aa),
- 3-[3-(2-Chloroethoxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 61aa),
- 20 2-(Cyclopentyloxy)-4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 62aa),
- 3-(4-Butoxy-3-isobutoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 63aa),
- 3-(3-Isobutoxy-4-propoxyphe nyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 64aa),
- 3-[3-Butoxy-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 65aa),
- 25 3-(3-Butoxy-4-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 66aa),
- 3-[3-Butoxy-4-(cyclohexyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
67aa),

48

- 3-[3-(Cyclohexylmethoxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 68aa),
- 3-[3-(Cyclohexylmethoxy)-4-isopropoxyphe<sup>n</sup>nyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 69aa),
- 5 3-[4-Butoxy-3-(cyclohexylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 70aa),
- 3-(4-Isobutoxy-3-isopropoxyphe<sup>n</sup>nyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 71aa),
- 3-(4-Butoxy-3-isopropoxyphe<sup>n</sup>nyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 72aa),
- 10 10 3-[4-(Cyclohexylmethoxy)-3-isopropoxyphe<sup>n</sup>nyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 73aa),
- 3-[3-Isopropoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 74aa),
- 15 3-[3-(Cyclopropylmethoxy)-4-isopropoxyphe<sup>n</sup>nyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 75aa),
- 3-[3-(Cyclopropylmethoxy)-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 76aa),
- 3-[4-Butoxy-3-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 77aa),
- 20 20 3-[3-(Cyclopropylmethoxy)-4-isopropoxyphe<sup>n</sup>nyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 78aa),
- 3-(3-Isobutoxy-4-isopropoxyphe<sup>n</sup>nyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 79aa),
- 25 3-[4-(Cyclopropylmethoxy)-3-isobutoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 80aa),

49

3-[4-(cyclohexyloxy)-3-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 81aa),

3-[4-(Cyclohexylmethoxy)-3-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 82aa),

5 3-[4-(Cyclopropylmethoxy)-3-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene

(Compound No. 83aa),

3-[3-(Cyclopentyloxy)-4-isobutoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 84aa),

10 3-[3-(Cyclopentyloxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
85aa),

3-[3-(Cyclopropylmethoxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 86aa),

3-[4-(Cyclopentyloxy)-3-isobutoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 87aa),

15 3-[3-Isopropoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 88aa),

3-(4-Ethoxy-3-isobutoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 89aa),

3-[3-(Cyclopentyloxy)-4-propoxyphe nyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 90aa),

20 3-[4-Butoxy-3-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
91aa),

3-[3-(Cyclopentyloxy)-4-isopropoxyphe nyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 92aa),

25 3-[3-(Cyclopentyloxy)-4-(cycloheptyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 93aa),

50

- 3-[3-(Cyclopentyloxy)-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 94aa),
- 3-[4-(Cyclohexylmethoxy)-3-isobutoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 95aa),
- 5 3-[4-(Cyclohexylmethoxy)-3-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 96aa),
- 3-[3-(Cyclopropylmethoxy)-4-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 97aa),
- 10 3-[4-(Cyclopentyloxy)-3-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 98aa),
- 3-[4-(Cyclopropylmethoxy)-3-isopropoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 99aa),
- 3-[4-(Cyclopentyloxy)-3-isopropoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 100aa),
- 15 3-(3-Isopropoxy-4-propoxypyhenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 101aa),
- 3-(4-Ethoxy-3-isopropoxypyhenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 102aa),
- 3-[3-Butoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene
- 20 (Compound No. 103aa),
- 3-[3-Butoxy-4-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 104aa),
- 3-(3-Butoxy-4-propoxypyhenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 105aa),
- 3-(3-Butoxy-4-isopropoxypyhenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.
- 25 106aa),

51

- 3-[3-(Cyclohexylmethoxy)-4-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 107aa),
- 3-[3-(Cyclohexylmethoxy)-4-isobutoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 108aa),
- 5 3-[3-(Cyclohexylmethoxy)-4-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 109aa),
- 3-[3-(Cyclohexylmethoxy)-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 110aa),
- 10 3-[4-(Cyclohexylmethoxy)-3-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 111aa),
- 3-[4-(Cyclopropylmethoxy)-3-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 112aa),
- 3-[4-(Cyclopentyloxy)-3-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 113aa),
- 15 3-[4-(3-Isobutoxy)-3-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
114aa),
- 3-[3-(Cycloheptyloxy)-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 115aa),
- 20 3-[3-(Cycloheptyloxy)-4-propoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 116aa),
- 3-[4-Butoxy-3-(cycloheptyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
117aa),
- 3-[3-(Cycloheptyloxy)-4-isopropoxypyhenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 118aa),
- !5 3-[3-(Cycloheptyloxy)-4-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 119aa),

52

- 3-(3-Ethoxy-4-propoxypyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 120aa),  
3-[4-(Cycloheptyloxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 121aa),  
3-[4-(Cyclopropylmethoxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
5 No. 122aa),  
3-[4-(Cyclohexylmethoxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 123aa),  
(S)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 124aa),  
10 3-(3-Butoxy-4-isobutoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 125aa),  
3-(3-Ethoxy-4-isopropoxypyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
126aa),  
3-[4-(Cyclopentyloxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
127aa),  
15 3-(4-Butoxy-3-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 128aa),  
3-(3-Ethoxy-4-isobutoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 129aa),  
3-[3-(Cycloheptyloxy)-4-isobutoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound  
No. 130aa),  
3-[3-(Cycloheptyloxy)-4-(cyclopentyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
20 (Compound No. 131aa),  
3-[3-(Cycloheptyloxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No.  
132aa),  
3-(4-Butoxy-3-propoxypyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 133aa),  
3-(4-Ethoxy-3-propoxypyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 134aa),  
25 3-[4-(Morpholin-4-ylethoxy)-3-propoxypyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 135aa),

- 3-(4-Isopropoxy-3-propoxypyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 136aa),  
2-[5-(1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]cyclopentanol (Compound No. 137aa),  
5 N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl}-2-fluorobenzamide (Compound No. 138aa),  
N-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl}benzamide (Compound No. 139aa),  
3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-4,5,6,6a-tetrahydro-3a*H*-pyrrolo[3,4-*d*]isoxazole  
10 (Compound No. 140aa),  
7-(Cyclopentylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.5]dec-2-ene (Compound No. 141aa),  
Tert-butyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-3a,4,6,6a-tetrahydro-5*H*-pyrrolo[3,4-*d*]isoxazole-5-carboxylate (Compound No. 142aa),  
15 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide (Compound No. 143aa),  
N-Butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.5]dec-2-ene-7-carboxamide (Compound No. 144aa),  
20 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-(methylsulfonyl)-1-oxa-2,7-diazaspiro[4.5]dec-2-ene (Compound No. 145aa),  
3-[4-Methoxy-3-(pyridin-3-ylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 146aa),  
5-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5,6,6a-tetrahydro-3a*H*-pyrrolo[3,4-*d*]isoxazole (Compound No. 147aa),  
25 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-5-(methylsulfonyl)-4,5,6,6a-tetrahydro-3a*H*-pyrrolo[3,4-*d*]isoxazole (Compound No. 148aa),

54

- 4-Bromo-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 149aa),
- 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,5,6,7a-tetrahydro-1,2-benzisoxazol-7(4H)-one  
(Compound No. 150aa),
- 5 3-[4-(Difluoromethoxy)-3-(2,3-dihydro-1*H*-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 151aa),
- 3-[4-(Cyclopentyloxy)-3-(2,3-dihydro-1*H*-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 152aa),
- 3-[4-Butoxy-3-(2,3-dihydro-1*H*-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
10 (Compound No. 153aa),
- 3-(3-{[3-(Benzyl)oxy]cyclopentyl}oxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 154aa),
- 7-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-oxa-2,7-diazaspiro[4.5]dec-2-ene  
(Compound No. 155aa),
- 15 3-[4-Methoxy-3-(pyridin-2-ylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 156aa),
- 3-[3-(2,3-Dihydro-1*H*-inden-2-yloxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
20 (Compound No. 157aa),
- 3-[3-(2,3-Dihydro-1*H*-inden-2-yloxy)-4-propoxyphephenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
(Compound No. 158aa),
- 3-[4-(Cyclopropylmethoxy)-3-(2,3-dihydro-1*H*-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 159aa),
- 3-[3-(2,3-Dihydro-1*H*-inden-2-yloxy)-4-isopropoxyphephenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene  
25 (Compound No. 160aa),
- 2-(2,3-Dihydro-1*H*-inden-2-yloxy)-4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol  
(Compound No. 161aa),

*N*-cyclopropyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetamide (Compound No. 162aa),

Hydrochloride salt of 3-[4-methoxy-3-(piperidin-3-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 163aa),

5 2-[5-(1,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetamide (Compound No. 164aa),

Ethyl [5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetate (Compound No. 165aa),

10 [5-(1,7-Dioxa-2-aza spiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetonitrile (Compound No. 166aa), and

3-{3-[(2,6-Dichloropyridin-4-yl)methoxy]-4-methoxyphenyl}-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 167aa),

and any pharmaceutically acceptable acid addition salts thereof.

Pharmaceutically acceptable acid addition salts include, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid. In some embodiments, such salts include acetate, hydrochloride, hydrobromide, sulfate, phosphate, and methanesulfonate.

Suitable p38 kinase inhibitors include those disclosed in co-pending U.S. Patent 20 Application No. 60/605,344, for example,

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalen-1-yl]urea;

25 1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-ylethoxy)naphthalen-1-yl]urea; and

56

1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea,

and any pharmaceutically acceptable acid addition salts thereof.

Other suitable p38 MAP kinase inhibitors include, for example, compounds disclosed

5 in co-pending U.S. Patent Application Nos. 60/598621 and 60/630,517 and Indian Patent Application Nos. 1098/DEL/2005 and 211/DEL/2005, as well as:

1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea;

10 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid tert-butyl ester;

Hydrochloride salt of 2-(Piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

2-(1-Methanesulfonyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

15 2-(1-Benzyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

2-(1-Methyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

20 2-(4-Methyl-piperazin-1-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

4-[6-(2-Chloro-phenyl)-7-oxo-8-(tetrahydro-pyran-4-yl)-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid tert-butyl ester;

2-(Piperidin-1-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

25 2-Cyclobutylamino-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;

- 2-(1-Acetyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;
- 2-(1-Benzoyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;
- 5 2-(1-Benzoyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;
- 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid (4-fluoro-phenyl)-amide;
- 2-(1-Ethanesulfonyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;
- 10 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carbothioic acid (4-fluoro-phenyl)-amide;
- 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid (4-trifluoromethyl-phenyl)-amide;
- 15 2-[4-(Propane-2-sulfonyl)-piperazin-1-ylamino]-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one;
- 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid propylamide;
- 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid ((R)-1,2-dimethyl-propyl)-amide;
- 20 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid cyclohexylamide;
- 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid (4-fluoro-phenyl)-amide; and
- 25 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid cyclopentyl methyl-amide, and

and any pharmaceutically acceptable acid addition salts thereof.

Pharmacologically acceptable acid addition salts include, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, and maleic acid.

5       The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.

10      Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-dibenzylethylenediamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and tromethamine.

20      When a compound is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids, such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, nitric, pantothenic, phosphoric, succinic, sulfuric, tartaric, and p-toluenesulfonic acid.

25      Pharmaceutical compositions described herein may be administered by following routes, for example, oral, topical, intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, subcutaneous, intranasally, inhalation, rectally or vaginally.

Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, suppositories, troches, patches, gel caps, magmas, lozenges, creams, pastes, plasters, lotions, discs, or ointments. Liquid form preparations include solutions suspensions, emulsions, syrups, elixirs, aerosols, inhalations, nasal sprays or oral sprays.

- 5 Active compounds can be admixed under sterile condition with pharmaceutically acceptable carrier and any needed preservatives or buffer as may be required.

Pharmaceutical compositions for use in the methods described herein may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association one or more active compounds with one or more carriers or excipients. In general, 10 pharmaceutical compositions are prepared by uniformly and intimately admixing the active compounds with one or more pharmaceutically acceptable liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired form.

Commonly used carriers include one or more of corn starch, lactose, talc, calcium phosphate, calcium sulphate, calcium stearate, magnesium stearate, steane acid, sorbitol, 15 microcrystalline cellulose, mannitol, gelatin, natural or synthetic gums, such as carboxymethylcellulose, methylcellulose, alginate, dextran, acacia gum, karaya gum, locust bean gum. Additionally, other excipients such as diluents, binders, lubricants, disintegrants, colors and flavoring agents may be employed. For example, a tablet may be prepared by compression or molding, optionally with one or more pharmaceutically acceptable excipient. 20 Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.

25 In addition to the common dosage forms set out above, the therapeutically active ingredients may also be administered by controlled release means and/or delivery devices to provide the rate-controlled release of any one or more of the components or active ingredients to optimize the desired therapeutic effects. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release

60

polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.

The “polymeric matrix” serves essentially to modulate drug release kinetics and to stabilize metastable drug. Due to their versatility, polymers represent election material for matrix delivery systems. Polymeric matrices can be used in, for example, oral delivery, implantable systems, tissue engineering, DNA/RNA release, intelligent delivery systems and polymer conjugation.

The magnitude of a prophylactic or therapeutic dose of one or more compounds described herein in the acute or chronic prevention, treatment, or management of a disorder or condition will vary with the severity of the condition to be treated and the route of administration. The dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual patient. Suitable total daily dose ranges can be readily determined by those skilled in the art.

The MRA and  $\beta$ 2-agonists may be present in ratios from about 1:10 to 10:1. The MRA and  $\beta$ 2-agonists may also be present in ratios of about 1:1, 2:1, 1:2, 1:3, 3:1, 1:5 and even 5:1.

The MRA and corticosteroids may be present in ratios from about 1:10 to 10:1. The MRA and corticosteroids may also be present in ratios of about 1:1, 2:1, 1:2, 1:3, 3:1, 1:5 and even 5:1.

The MRA and p38 MAP kinase inhibitors may be present in ratios from about 1:10 to 10:1. The MRA and p38 MAP kinase inhibitors may also be present in ratios of about 1:1, 2:1, 1:2, 1:3, 3:1, 1:5 and even 5:1.

The MRA and PDE-IV inhibitors may be present in ratios from about 1:10 to 10:1. The MRA and PDE-IV inhibitors may also be present in ratios of about 1:1, 2:1, 1:2, 1:3, 3:1, 1:5 and even 5:1.

Suitable dosage amounts can be determined using small dosages that are less than the optimum dose. Such small dosages can be increased in small increments until the optimum effect is reached. Dosage amounts may be divided and administered as divided doses if desired.

The present invention also provides for methods of treating or preventing autoimmune, inflammatory, or allergic disorders. The method comprises administering to a mammal in need thereof a pharmaceutical composition comprising therapeutically effective amounts of one or more MRA of Formulae I, II, or III described herein, and at least one additional active ingredients selected from one or more  $\beta$ 2-agonists, p38 MAP kinase, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents.

In one embodiment, there is provided methods for treating or preventing autoimmune and/or inflammatory/allergic diseases or disorders comprising administering one or more compounds of pharmaceutical compositions described herein. Such autoimmune and/or inflammatory/allergic diseases or disorder include, for example, respiratory disorder, asthma, chronic bronchitis, chronic obstructive pulmonary disease, whooping cough, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, eczema, inflammatory bowel disease, endotoxic shock, anaphylactic shock, laminitis in horses, septic shock, ulcerative colitis, crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, periodontitis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, infant respiratory distress syndrome, transplant rejection, rhinitis, pruritus, diabetes insipidus, eye diseases, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, osteoporosis, osteoarthritis, inflammation, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal induced septic shock, viral induced septic shock, inflammation-mediated chronic tissue degeneration, cytokine-mediated chronic tissue degeneration, osteoarthritis, cancer, cachexia, muscle wasting, depression memory impairment, tumor growth, cancerous invasion of normal tissues Hashimoto's thyroiditis (underactive thyroid), Graves' disease (overactive thyroid), Lupus and acquired immuno deficiency syndrome.

In some embodiments, methods of treating or preventing autoimmune, inflammatory or allergic disorders include concurrent or sequential administration to a mammal in need thereof: a) a pharmaceutical composition comprising a therapeutically effective amount of one

- or more compounds described, and one or more pharmaceutically acceptable carriers, excipients or diluents; and b) one or more pharmaceutical compositions comprising therapeutically effective amounts of at least one active ingredient selected from one or more of  $\beta$ 2-agonists, one or more p38 MAP kinase inhibitors, one or more PDE-IV inhibitors, one 5 or more corticosteroids and one or more pharmaceutically acceptable carriers, excipients or diluents.

In some embodiments, methods of treating or preventing autoimmune, inflammatory or allergic disorders include concurrent or sequential administration to a mammal in need thereof: a) a pharmaceutical composition comprising a therapeutically effective amount of one 10 or more compounds described herein, and one or more pharmaceutically acceptable carriers, excipients or diluents; and b) one or more pharmaceutical compositions comprising therapeutically effective amounts of at least one active ingredient selected from one or more of anticholinergics, one or more dopamine agonists, one or more antiallergics, one or more PAF antagonists, one or more leukotriene antagonists, one or more EGFR kinase inhibitors, 15 one or more additional muscarinic receptor antagonists, or combinations thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.

MRA compounds described herein may be used on their own or in conjunction with other active MRA compounds known in the art. MRA compounds described herein may also be used in combination with other pharmaceutically active substances. These may be, for 20 example, one or more anticholinergics, dopamine agonists, antiallergics, PAF antagonists, leukotriene antagonists, EGFR kinase inhibitors, MRAs, or mixtures thereof.

Suitable anticholinergics include, but are not limited to, anticholinergics known in the art, as well as tiotropium salts, ipratropium salts, oxitropium salts, salts of one or more compounds disclosed in WO 02/32899; tropenol N-methyl-2,2-diphenylpropionate, scopine 25 N-methyl-2,2-diphenylpropionate, scopine N-methyl-2-fluoro-2,2-diphenylacetate and tropenol N-methyl-2-fluoro-2,2-diphenylacetate; as well as salts of the compounds disclosed in WO 02/32898; tropenol N-methyl-3,3',4,4'-tetrafluorobenzilate, scopine N-methyl-3,3',4,4'-tetrafluorobenzilate, scopine N-methyl-4,4'-dichlorobenzilate, scopine N-methyl-4,4'-difluorobenzilate, tropenol N-methyl-3,3'-difluorobenzilate, scopine N-methyl-3,3'

difluorobenzilate, and tropenol N-ethyl-4,4'-difluorobenzilate, optionally in hydrate and solvate forms thereof. Salts include abovementioned cations, and anions including, for example, chloride, bromide, and methanesulfonate. In some embodiments, salts include bromide or methanesulfonate salts of such compounds.

- 5 Suitable anticholinergics include, but are not limited to, anticholinergics known in the art, as well as one or more of tiotropium bromide, ipratropium bromide, oxitropium bromide, tropenol 2,2-diphenylpropionate methobromide, scotine 2,2-diphenylpropionate methobromide, scotine 2-fluoro-2,2-diphenylacetate methobromide, tropenol 2-fluoro-2,2-diphenylacetate methobromide, tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, scotine 10 3,3',4,4'-tetrafluorobenzilate methobromide; scotine 4,4'-dichlorobenzilate methobromide, scotine 4,4'-difluorobenzilate methobromide, tropenol 3,3'-difluorobenzilate methobromide, scotine 3,3'-difluorobenzilate methobromide, tropenol 4,4'-difluorobenzilate ethylbromide or mixtures thereof. In some embodiments, anticholinergics include one or more of tiotropium bromide, ipratropium bromide, tropenol 2,2-diphenylpropionate methobromide, scotine 2,2-15 diphenylpropionate methobromide, scotine 2-fluoro-2,2-diphenylacetate methobromide, tropenol 2-fluoro-2,2-diphenylacetate methobromide or mixtures thereof.

Suitable corticosteroids include, but are not limited to, corticosteroids known in the art, as well as one or more of flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, GW 215864, KSR 592, ST-126, 20 dexamethasone or mixtures thereof. In some embodiments, the corticosteroids can be selected from one or more of flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, dexamethasone or mixtures thereof; from one or more of budesonide, fluticasone, mometasone, ciclesonide or mixtures thereof; and fluticasone. Suitable corticosteroids include salts or derivatives thereof, including, for example, sodium 25 salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates, or furoates. In some embodiments, corticosteroids are in the form of their hydrates.

Suitable PDE-IV inhibitors include, but are not limited to, PDE-IV inhibitors known in the art, as well as one or more compounds disclosed in WO 2005/021515 and co-pending

Indian Patent Application No. 303/DEL/2005, compounds disclosed hereinabove; as well as one or more of enprofylline, roflumilast, ariflo, Bay-19 8004, CP-325, 366, BY343, D-4396 (Sch-351591), V-11294A, Z-15370, AWD-12-281; or mixtures thereof. In some embodiments, suitable PDE-IV inhibitors can be selected from one or more of enprofylline, 5 roflumilast, ariflo, Z15370, AWD-12-281, compounds disclosed in WO 2005/021515 and co-pending Indian Patent Application No. 303/DEL/2005 or mixtures thereof. In other embodiments, the suitable PDE-IV inhibitor can be AWD-12-281. PDE-IV inhibitors can include any pharmaceutically acceptable acid addition salts thereof, which may exist. Pharmaceutically acceptable salts can be selected from salts of hydrochloric acid, 10 hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid. In some embodiments, the salts can be selected from acetate, hydrochloride, hydrobromide, sulfate, phosphate, and methanesulfonate.

Suitable dopamine agonists include, but are not limited to, dopamine agonists known 15 in the art, as well as one or more of bromocriptine, cabergolin,  $\alpha$ -dihydroergocryptine, lisuride, pergolide, pramipexol, roxindole, ropinirole, talipexole, terguride, viozan or mixtures thereof. In some embodiments, suitable dopamine agonists can be selected from one or more of pramipexol, talipexole, viozan or mixtures thereof. Dopamine agonists include pharmaceutically acceptable acid addition salts and hydrates thereof, which may exist. 20 Pharmaceutically acceptable acid addition salts can be selected from salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, and maleic acid.

Suitable antiallergic agents include, but are not limited to, antiallergic agents known in 15 the art, as well as, one or more of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifene, emedastine, dimetindene, clemastine, bamipine, hexachloropheniramine, pheniramine, doxylamine, chlorophenoxyamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratadine, meclizine or mixtures thereof. In some embodiments, suitable antiallergic agents can be selected from one or more of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, ebastine, 20 desloratadine, mizolastine or mixtures thereof; as well as, epinastine, desloratadine or

mixtures thereof. Antiallergic agents include pharmaceutically acceptable acid addition salts thereof, which may exist.

Suitable PAF antagonists include, but are not limited to, PAF antagonists known in the art, as well as one or more of 4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-

- 5 1-yl]-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 6-(2-chlorophenyl)-8,9-dihydro-1-methyl-8-[(4-morpholinyl)carbonyl]-4H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine or mixtures thereof.

Suitable EGFR kinase inhibitors include, but are not limited to, EGFR kinase inhibitors known in the art, as well as one or more of 4-[(3-chloro-4-fluorophenyl)amino]-7-

- 10 (2-{4-[(S)-(2-oxotetrahydrofuran-5-yl)carbonyl]piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((S)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((R)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-7-[2-((S)-6-methyl-15 2-oxomorpholin-4-yl)ethoxy]-6-[(vinylcarbonyl)amino]quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)ethyl]-N-[(ethoxycarbonyl)methyl]-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline, 4-[(R)-(1-phenylethyl)amino]-6-{{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-20 methoxyquinazoline or mixtures thereof. EGFR kinase inhibitors include pharmaceutically acceptable acid addition salts thereof, which may exist. Pharmaceutically acceptable acid addition salts include, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid. For example, salts of EGFR kinase inhibitors can be selected from salts of acetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and methanesulfonic acid.

Suitable p38 kinase inhibitors include, but are not limited to, p38 kinase inhibitors known in the art, as well as one or more of 1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; 1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-

- (2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalen-1-yl]urea; 1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-ylethoxy)naphthalen-1-yl]urea; 1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; 1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea or mixtures thereof (disclosed in co-pending U.S. Patent Application No. 60/605,344);
- 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid tert-butyl ester; Hydrochloride salt of 2-(Piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(1-
- 10 Methanesulfonyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(1-Benzyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(1-Methyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(4-Methyl-piperazin-1-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 4-[6-(2-Chloro-phenyl)-7-oxo-8-
- 15 (tetrahydro-pyran-4-yl)-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid tert-butyl ester; 2-(Piperidin-1-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-Cyclobutylamino-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(1-Acetyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(1-Benzoyl-piperidin-4-ylamino)-8-
- 20 (tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 2-(1-Benzoyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid (4-fluoro-phenyl)-amide; 2-(1-Ethanesulfonyl-piperidin-4-ylamino)-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 4-[7-Oxo-8-
- 25 (tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carbothioic acid (4-fluoro-phenyl)-amide; 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperidine-1-carboxylic acid (4-trifluoromethyl-phenyl)-amide; 2-[4-(Propane-2-sulfonyl)-piperazin-1-ylamino]-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-8H-pyrido[2,3-d]pyrimidin-7-one; 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid propylamide; 4-[7-

Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid ((R)-1,2-dimethyl-propyl)-amide; 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid cyclohexylamide; 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid (4-fluoro-phenyl)-amide; 4-[7-Oxo-8-(tetrahydro-pyran-4-yl)-6-o-tolyl-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-piperazine-1-carboxylic acid cyclopentyl methyl-amide; one or more compounds disclosed in co-pending U.S. Patent Application Nos. 60/598621 and 60/630,517 and Indian Patent Application Nos. 1098/DEL/2005 and 211/DEL/2005; or mixtures thereof. p38 kinase inhibitors include pharmaceutically acceptable acid addition salts thereof, which may exist. Pharmaceutically acceptable salts can be selected from salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, and maleic acid.

Suitable muscarinic receptor antagonists include substances that directly or indirectly block activation of muscarinic cholinergic receptors. Examples include, but are not limited to, quaternary amines (*e.g.*, methantheline, ipratropium, propantheline), tertiary amines (*e.g.*, dicyclomine, scopolamine) and tricyclic amines (*e.g.*, telenzépine).

Other suitable muscarinic receptor antagonists include benztrapine (commercially available as COGENTIN from Merck), hexahydro-sila-difenidol hydrochloride (HHSID hydrochloride disclosed in Lambrecht *et al.*, *Trends in Pharmacol. Sci.*, 10(Suppl):60 (1989); (+/-)-3-quinuclidinyl xanthene-9-carboxylate hemioxalate (QNX-hemioxalate; Birdsall *et al.*, *Trends in Pharmacol. Sci.*, 4:459 (1983); telenzepine dihydrochloride (Coruzzi *et al.*, *Arch. Int. Pharmacodyn. Ther.*, 302:232 (1989); and Kawashima *et al.*, *Gen. Pharmacol.*, 21:17 (1990)), and atropine.

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention. The examples are provided to illustrate particular aspects of the disclosure and do not limit the scope of the present invention as defined by the claims.

68  
Examples**Biological Assay Method:****Example 1. *In-vitro* functional assay to evaluate efficacy of “MRA” in combination with “PDE-IV inhibitors”**5    *Animals and anaesthesia:*

Guinea Pigs (400-600 gm) were procured and trachea was removed under anesthesia (sodium pentobarbital, 300 mg/kg i.p) and immediately kept in ice-cold Krebs Henseleit buffer. Indomethacin (10 $\mu$ M) was present throughout the KH buffer to prevent the formation of bronchoactive prostanooids.

10    *Trachea experiments:*

The tissue of adherent fascia was removed and cut into strips of equal size (with approx. 4-5 tracheal rings in each strip). The epithelium was removed by careful rubbing, minimizing damage to the smooth muscle. The trachea was opened along the mid-dorsal surface with the smooth muscle band intact and a series of transverse cuts made from alternate sides so that they do not transect the preparation completely. Opposite ends of the cut rings were tied with the help of a thread. The tissue was mounted in isolated tissue baths containing 10ml Krebs Henseleit buffer maintained at 37°C and bubbled with carbogen, at a basal tension of 1 gm. The buffer was changed 4-5 times for about an hour. Equilibration of the tissue was done for 1 hr for stabilization. After 1 hr, the tissue was challenged with 1 $\mu$ M carbachol. This was repeated after every 2-3 washes till two similar consecutive responses were obtained. At the end of stabilization, the tissues were incubated with suboptimal dose of MRA/ Vehicle for 20 minutes prior to contraction of the tissues with 1 $\mu$ M carbachol. The relaxant activity of the PDE-IV inhibitor [10 $^{-9}$  M to 10 $^{-4}$  M] on the stabilized developed tension/response was subsequently assessed. The contractile response of tissues was recorded either on Powerlab data acquisition system or on Grass polygraph (Model 7). The relaxation was expressed as percentage of maximum carbachol response and EC<sub>25</sub> was calculated as the concentration producing 25% of the maximum relaxation to 1 $\mu$ M carbachol. The percent relaxation

between the treated and control tissues were compared using non-parametric unpaired t-test. A p value of < 0.05 is considered to be statistically significant.

Preincubation of tissues with C No. 66 at 1nM before contraction with carbachol potentiated the subsequent relaxant activity of C No. 124aa, roflumilast and rolipram. This was apparent from the slight but significant shift in the -log[EC<sub>25</sub>] value from 4.40 to 5.53 for C No. 124aa (p<0.05) & from 4.46 to 6.25 for roflumilast (p<0.01) in the presence of C No. 66. There was no significant potentiation of the response for rolipram in the presence of C No. 66 (p>0.05)

10 **Table1: Potency of the compounds for relaxing carbachol precontracted guinea-pig isolated trachea**


Treatment	Tension(gm)		- Log [EC <sub>25</sub> ]	EC <sub>25</sub> (μM)
	Before carbachol challenge	After carbachol challenge		
<b>C No. 124aa (n=3)</b>	1.84±0.32	1.99±0.40	4.40	41.8
<b>C No. 66 (1nM)+ C No. 124aa (n=3)</b>	2.43±0.38	2.25±0.19	5.53	9.8*
<b>Rolipram (n=2)</b>	1.24±0.04	1.16±0.30	5.25	7.6
<b>C No. 66 (1nM)+Rolipram (n=2)</b>	1.15±0.23	1.23±0.29	6.00	1.1 <sup>ns</sup>
<b>Roflumilast (n=5)</b>	1.38±0.22	1.57±0.22	4.46	44.2
<b>C No. 66 1nM)+Roflumilast (n=2)</b>	1.39±0.32	1.33±0.30	6.25	0.66@

n : number of experiments; \* : (p<0.05) vs 14016; ns: (p>0.05) vs Rolipram;  
@ : (p<0.01) vs Roflumilast


15 C No. 66 and C No. 124aa refers to Compound No. 66 and 124aa, respectively.

**In-vitro effect on guinea pig trachea**


**A: Effect of C No. 66**



**B: Effect of C.N.66**



**C: Effect of C.N.66**



*Relaxant activity of C No.124aa, roflumilast & rolipram in guinea pig trachea pre-contracted with carbachol in the presence of C No.66*

Example 2. In-vivo assay to evaluate efficacy of MRA in combination with PDE-IV inhibitors


Drug treatment:

5 MRA (1ng/kg to 1mg/kg) and PDE-IV inhibitor (1ng/kg to 1mg/kg) were instilled intratracheally under anesthesia either alone or in combination.

Method:

Wistar rats weighing 200±20gm were used in the study. Rats had free access to food and water. On the day of experiment, animals were exposed to lipopolysaccharide (LPS, 10 100µg/ml) for 40 min. One group of vehicle treated rats was exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals were placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing concentration of acetylcholine (1, 6, 12, 24, 48 and 96 mg/ml) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone. 15 The respiratory parameters were recorded online using Bio system XA software, (Buxco Electronics, USA). Penh, at any chosen dose of acetylcholine was, expressed as percent of PBS response and the using a nonlinear regression analysis PC100 (2 folds of PBS value) values computed.

A synergistic effect was observed with the combination of muscarinic receptor 20 antagonist (MRA) with PDE 4 inhibitor which can be seen from below mentioned graphs.



- C No. 66 refers to Compound No. 66
- C No. 124aa refers to Compound No. 124aa
- Combining C No. 124aa (PDEIV inhibitor) – 6 $\mu$ g and C No. 66 (MRA)-10 ng results in synergistic effect

5

Example 3. In-vivo assay to evaluate efficacy of MRA in combination with Corticosteroids

Ovalbumin induced early phase bronchoconstriction and airway inflammation:

Guinea pigs are sensitised on days 0, 7 and 14 with 50- $\mu$ g ovalbumin and 10 mg

10 aluminium hydroxide injected intraperitoneally. On days 19 and 20 guinea pigs are exposed to 0.1% w v<sup>-1</sup> ovalbumin or PBS for 10 min, and with 1% ovalbumin for 30 min on day 21. Guinea pigs are treated with test compound or standard or vehicle once daily from day 19 and continued for 4 days.

5

Ovalbumin induced early phase bronchoconstriction

On day 21, after drug or vehicle administration, basal respiratory parameters are recorded using Whole body Plethysmograph (Biosystem XA software, Buxco Electronics, USA) followed by challenge with 1% ovalbumin/PBS for 10 min duration. For recording basal

- 5 respiratory parameters, 10 consecutive 1 min readings are averaged. Each 1 min. reading represents an average of each breadth taken in that 60 sec duration. Following PBS/Ovalbumin challenge data is recorded for 120 min, which represented hundred and twenty recordings one min apart. Each 1 min recording is an average of all the breath in 1 min. PenH, at any chosen time point post challenge is expressed as percent of basal response.
- 10 These values are plotted against time using Graphpad prism software (GraphPad Software Inc, USA) and Area Under the Curve (AUC) is computed. Percent inhibition is computed using the following formula.

$$\text{Percent Inhibition} = \frac{\text{AUC}_{\text{OVA}} - \text{AUC}_{\text{TEST}}}{\text{AUC}_{\text{OVA}} - \text{AUC}_{\text{PBS}}} \times 100$$

15 Where,

$\text{AUC}_{\text{OVA}}$  = AUC in vehicle treated group challenged with ovalbumin

$\text{AUC}_{\text{TEST}}$  = AUC in group treated with a given dose of test compound

$\text{AUC}_{\text{PBS}}$  = AUC in vehicle treated group challenged with PBS

20 Ovalbumin induced airway inflammation

24 hrs after the final ovalbumin challenge BAL is performed using Hank's balanced salt solution (HBSS). Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in 1ml HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and eosinophil count are expressed as cell count (millions cells ml<sup>-1</sup> of BAL). Eosinophil is also expressed as percent of total leukocyte count. % inhibition is computed using the following formula.

$$\text{% Inhibition} = \frac{\text{Eos}_{\text{OVA}} - \text{Eos}_{\text{TEST}}}{\text{Eos}_{\text{OVA}} - \text{Eos}_{\text{CON}}} \times 100$$

30

Where,

$EosOVA$  = Percentage of eosinophil in vehicle treated group challenged with ovalbumin

$EosTEST$  = Percentage of eosinophil in group treated with a given dose of test compound

$EosCON$  = Percentage of eosinophil in vehicle treated group challenged with PBS.

- 5 Example 4. In-vivo assay to evaluate efficacy of "MRA" in combination with p38 MAP kinase inhibitors

Lipopolysaccharide (LPS) induced airway hyperreactivity (AHR) and neutrophilia:

Drug treatment:

- 10 MRA (1ng/kg to 1mg/kg) and p38 MAP kinase inhibitor (1ng/kg to 1mg/kg) are instilled intratracheally under anesthesia either alone or in combination.

Method:

Male wistar rats weighing  $200\pm20$ gm are used in the study. Rats have free access to food and water. On the day of experiment, animals are exposed to lipopolysaccharide (LPS,  $100\mu\text{g}/\text{ml}$ ) for 40 min. One group of vehicle treated rats is exposed to phosphate buffered saline (PBS) for 40 min. Two hours after LPS/PBS exposure, animals are placed inside a whole body plethysmograph (Buxco Electronics, USA) and exposed to PBS or increasing acetylcholine (1, 6, 12, 24, 48 and  $96\text{ mg}/\text{ml}$ ) aerosol until Penh values (index of airway resistance) of rats attained 2 times the value (PC-100) seen with PBS alone. The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA).

- 15 20 Penh, at any chosen dose of acetylcholine is, expressed as percent of PBS response and the using a nonlinear regression analysis PC100 (2 folds of PBS value) values are computed. Percent inhibition is computed using the following formula.

$$\% \text{ Inhibition} = \frac{\text{PC100}_{\text{LPS}} - \text{PC100}_{\text{TEST}}}{\text{PC100}_{\text{LPS}} - \text{PC100}_{\text{PBS}}} \times 100$$

Where,

$\text{PC100}_{\text{LPS}}$  = PC100 in vehicle treated group challenged group with LPS

$\text{PC100}_{\text{TEST}}$  = PC100 in group treated with a given dose of test compound

$\text{PC100}_{\text{PBS}}$  = PC100 in vehicle treated group challenged with PBS

75

Immediately after the airway hyperreactivity response is recorded, animals are sacrificed and bronchoalveolar lavage (BAL) is performed. Collected lavage fluid is centrifuged at 3000 rpm for 5 min, at 4°C. Pellet is collected and resuspended in 1ml HBSS. Total leukocyte count is performed in the resuspended sample. A portion of suspension is cytocentrifuged and stained with Leishmann's stain for differential leukocyte count. Total leukocyte and Neutrophil counts are expressed as cell count (millions cells ml<sup>-1</sup> of BAL). Percent inhibition is computed using the following formula.

$$\text{10 } \% \text{ Inhibition} = \frac{\text{NC}_{\text{LPS}} - \text{NC}_{\text{TEST}}}{\text{NC}_{\text{LPS}} - \text{NC}_{\text{PBS}}} \times 100$$

Where,

$\text{NC}_{\text{LPS}}$  = Percentage of neutrophil in vehicle treated group challenged with LPS

$\text{NC}_{\text{TEST}}$  = Percentage of neutrophil in group treated with a given dose of test compound

$\text{NC}_{\text{PBS}}$  = Percentage of neutrophil in vehicle treated group challenged with PBS

15 The percent inhibition data is used to compute ED<sub>50</sub> values using Graph Pad Prism software (Graphpad Software Inc., USA).

Example 5. In-vivo assay to evaluate efficacy of "MRA" in combination with  $\beta_2$ -agonists

Drug treatment:

20 MRA (1ng/kg to 1mg/kg) and long acting  $\beta_2$  agonist are instilled intratracheally under anesthesia either alone or in combination.

Method

25 Wistar rats (250-350gm) or balb/C mice (20-30gm) are placed in body box of a whole body plethysmograph (Buxco Electronics., USA) to induce bronchoconstriction. Animals are allowed to acclimatise in the body box and are given successive challenges, each of 2 min duration, with PBS (vehicle for acetylcholine) or acetylcholine (i.e. 24, 48, 96, 144, 384, and 768 mg/ml). The respiratory parameters are recorded online using Biosystem XA software, (Buxco Electronics, USA) for 3 min. A gap of 2 min is allowed for the animals to recover and then challenged with the next higher dose of acetylcholine (ACh). This step is repeated until Penh of rats attained 2 times the value (PC-100) seen with PBS challenge. Following

76

PBS/ACh challenge, Penh values (index of airway resistance) in each rat/mice is obtained in the presence of PBS and different doses of ACh. Penh, at any chosen dose of ACh is, expressed as percent of PBS response. The Penh values thus calculated are fed into Graph Pad Prism1 software (Graphpad Software Inc.,USA) and using a nonlinear regression analysis

- 5 PC100 (2 folds of PBS value) values are computed. Percent inhibition is computed using the following formula.

$$\text{Percent Inhibition} = \frac{\text{PC100}_{\text{TEST}} - \text{PC100}_{\text{CON}}}{768 - \text{PC100}_{\text{CON}}} \times 100$$

- 10 Where,

$\text{PC100}_{\text{CON}}$  = PC100 in vehicle treated group

$\text{PC100}_{\text{TEST}}$  = PC100 in group treated with a given dose of test compound


768 = is the maximum amount of acetylcholine used.

We Claim:

1        1. A pharmaceutical composition comprising one or more muscarinic receptor  
2 antagonists (“MRA”), and at least one additional active ingredients selected from one or more  
3  $\beta$ 2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids, anticholinergics,  
4 dopamine agonists, antiallergics, PAF antagonists, leukotriene antagonists, EGFR kinase  
5 inhibitors, different muscarinic receptor antagonists or a mixture thereof, wherein the MRA is  
6 one or more compounds having the structures of Formula I, II, or III, wherein:

7 a. Formula I is:

8



## Formula I

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein

12   **Ar**   represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected  
13           from oxygen, sulphur or nitrogen, wherein

the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>), N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;

**R<sub>1</sub>** represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino, alkoxy, carbamoyl or halogen (*e.g.*, fluorine, chlorine, bromine and iodine);

**R<sub>2</sub>** represents alkyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl ring, (C<sub>3</sub>-C<sub>7</sub>) cycloalkenyl ring, aryl, heterocyclic ring, or heteroaryl ring, wherein

78

the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms independently selected from oxygen, sulphur or nitrogen, and the aryl or heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;

W represents (CH<sub>2</sub>)<sub>p</sub>, wherein p represents 0 to 1;

X represents oxygen, sulphur, -NR or no atom (*i.e.*, a bond), wherein

R represents hydrogen or (C<sub>1</sub>-<sub>6</sub>) alkyl;

Y represents CHR<sub>5</sub>CO or (CH<sub>2</sub>)<sub>q</sub>, wherein

R<sub>5</sub> represents hydrogen or methyl, and

q represents 0 to 4;

Z represents oxygen, sulphur, or NR<sub>10</sub>, wherein

R<sub>10</sub> represents hydrogen, or C<sub>1</sub>-<sub>6</sub> alkyl;

Q represents (CH<sub>2</sub>)<sub>n</sub>, CHR<sub>8</sub> or CH<sub>2</sub>CHR<sub>9</sub>, wherein

n represents 0 to 4,

R<sub>8</sub> represents H, OH, C<sub>1</sub>-<sub>6</sub>, alkyl, C<sub>1</sub>-<sub>6</sub> alkenyl, or C<sub>1</sub>-<sub>6</sub> alkoxy, and

R<sub>9</sub> represents H, OH, lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or lower alkoxy (C<sub>1</sub>-C<sub>4</sub>);

R<sub>6</sub> and R<sub>7</sub> are independently selected from H, CH<sub>3</sub>, COOH, CONH<sub>2</sub>, NH<sub>2</sub> or CH<sub>2</sub>NH<sub>2</sub>; and


R<sub>4</sub> represents hydrogen or C<sub>1</sub>-C<sub>15</sub> saturated or unsaturated aliphatic hydrocarbon group, wherein

1 to 6 hydrogen atoms of C<sub>1</sub>-C<sub>15</sub> saturated or unsaturated aliphatic hydrocarbon group may be substituted with a group independently selected from halogen, arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms independently selected nitrogen, oxygen or sulphur, and

79

51                   any 1 to 3 hydrogen atoms on the ring of arylalkyl, aryl alkenyl,  
 52                   heteroarylalkenyl may be optionally substituted with lower alkyl (C<sub>1</sub>-  
 53                   C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxyl, nitro, lower  
 54                   alkoxycarbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhaloalkoxy  
 55                   (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkylamino (C<sub>1</sub>-C<sub>4</sub>), or N-lower  
 56                   alkylamino carbonyl (C<sub>1</sub>-C<sub>4</sub>);

57       b.      Formula II is:



58                   Formula II

59                   or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer,  
 60                   diastereomer, N-oxide, polymorph or metabolite thereof, wherein


61       **R<sub>1</sub>'** and **R<sub>2</sub>'** are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or phenyl, wherein  
 62                   phenyl is optionally substituted with one or more groups independently selected from  
 63                   C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen; and

64       **Z'**      represents oxygen or NR<sub>3</sub>, wherein

65       **R<sub>3</sub>**      represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

66

67       c.      Formula III is,



68                   Formula III

69                   or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer,  
 70                   diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein

80

71     $\mathbf{R}_1''$  and  $\mathbf{R}_2''$  are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen;

74     $\mathbf{R}_3'$  represents C<sub>1</sub>-C<sub>6</sub> alkyl, wherein

75                1-3 hydrogen atom(s) may be substituted with a group independently selected from C<sub>5</sub>-C<sub>7</sub> cycloalkyl, 1,3-dioxo-1,3-dihydro-isoindolyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected C<sub>1</sub>-C<sub>4</sub> alkyl or halogen; and

79     $\mathbf{Z}$  represents oxygen or NR<sub>4</sub>', wherein

80     $\mathbf{R}_4'$  represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

1                2. The pharmaceutical composition of claim 1, wherein the one or more MRA are  
2 selected from:

3    (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide (Compound No. 1)

5    (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 2)

7    (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 3)

9    (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate  
10 (Compound No. 4)

11 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 5)

13 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 6)

15 (1a,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 7)

81

- 17 (1a,5a,6a)-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-  
18 2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 8)
- 19 (1a,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-  
20 (aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 9)
- 21 (1a,5a,6a)-N-[3-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-  
22 (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 10)
- 23 (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-  
24 2-hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 11)
- 25 (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-  
26 2-hydroxy-2-cyclohexyl-2-phenyl acetate (Compound No. 12)
- 27 (1a,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-  
28 (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 13)
- 29 (1a,5a,6a)-N-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-  
30 (aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 14)
- 31 (1a,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-  
32 hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 15)
- 33 (1a,5a,6a)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-  
34 hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 16)
- 35 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
36 cyclohexyl-2-phenyl acetate (Compound No. 17)
- 37 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
38 cyclopentyl-2-phenyl acetate (Compound No. 18)
- 39 (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
40 cyclopentyl-2-phenyl acetate (Compound No. 19)
- 41 (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
42 cyclohexyl-2-phenyl acetate (Compound No. 20)

82

- 43 (1a,5a,6a)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
44 cyclohexyl-2-phenyl acetamide (Compound No. 21)
- 45 (1a,5a,6a)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
46 cyclopentyl-2-phenyl acetamide (Compound No. 22)
- 47 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2,2-  
48 diphenyl acetamide (Compound No. 23)
- 49 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2-  
50 cyclohexyl-2-phenyl acetamide (Compound No. 24)
- 51 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(1-aminoethyl)-yl]-2-hydroxy-2-  
52 cyclopentyl-2-phenyl acetamide (Compound No. 25)
- 53 (1a,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
54 cyclohexyl-2-phenyl acetate (Compound No. 26)
- 55 (1a,5a,6a)-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
56 cyclopentyl-2-phenyl acetate (Compound No. 27)
- 57 (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
58 cyclohexyl-2-phenyl acetamide (Compound No. 28)
- 59 (2R)-(+)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
60 cyclopentyl-2-phenyl acetamide (Compound No. 29)
- 61 (2R) (+)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
62 cyclohexyl-2-phenyl acetate (Compound No. 30)
- 63 (2R) (+)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
64 cyclopentyl-2-phenyl acetate (Compound No. 31)
- 65 (2S)-(-)- (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
66 cyclopentyl-2-phenyl acetamide (Compound No. 32)
- 67 (2S)-(-)-(1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
68 cyclopentyl-2-phenyl acetate (Compound No. 33)

83

- 69 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
70 cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt (Compound No. 34)
- 71 (2R)-(+) (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
72 cyclohexyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 35)
- 73 (2R)-(+) (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
74 cyclopentyl-2-phenyl acetamide. L-( + )-tartrate salt (Compound No. 36)
- 75 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
76 cyclobutyl-2-phenyl acetamide (Compound No. 37)
- 77 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
78 cyclopropyl-2-phenyl acetamide (Compound No. 38)
- 79 (1a,5a,6a)-N-[ 3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-  
80 hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 39)
- 81 (1a,5a,6a)-[ 3-(3,4- methylenedioxyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-  
82 hydroxy-2-cyclopentyl-2-phenyl acetate (Compound No. 40)
- 83 (1a,5a,6a)-[3-(2-(3,4-methylenedioxyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-  
84 2-hydroxy-2-cyclopentyl-2-phenyl acetate. L-(+)-tartrate salt (Compound No. 41)
- 85 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2 diphenyl acetate  
86 L(+)-tartrate salt (Compound No. 42)
- 87 (1a,5a,6a)- [3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-  
88 phenyl acetate L(+) tartrate salt (Compound No. 43)
- 89 (1a,5a,6a)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-  
90 phenyl acetate L(+) tartrate salt (Compound No. 44)
- 91 (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
92 2-cyclohexyl-2-phenyl acetamide (Compound No. 45)
- 93 (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
94 2-cyclohexyl-2-phenyl acetamide (Compound No. 46)

- 95 (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
96 2-cyclohexyl-2-phenyl acetamide (Compound No. 47)
- 97 (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
98 2-cyclopentyl-2-phenyl acetamide (Compound No. 48)
- 99 (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
100 2,2-diphenyl acetamide (Compound No. 49)
- 101 (1a,5a,6a)-N-[3-(4-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
102 2,2-diphenyl acetamide (Compound No. 50)
- 103 (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
104 2,2-diphenyl acetamide (Compound No. 51)
- 105 (1a,5a,6a)-N-[3-(2-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
106 2-cyclopentyl-2-phenyl acetamide (Compound No. 52)
- 107 (1a,5a,6a)-N-[3-(3-pyridylmethyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
108 2-cyclopentyl-2-phenyl acetamide (Compound No. 53)
- 109 (1a,5a,6a)-N-[3-(3-methyl-2-butenyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-  
110 hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 54)
- 111 (1a,5a,6a)-N-[3-(3,4-methylenedioxypyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-  
112 (aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide (Compound No. 55)
- 113 (1a,5a,6a)-N-[3-(3,4-methylenedioxypyphenyl)methyl-3-azabicyclo[3.1.0]hexyl-6-  
114 (aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide (Compound No. 56)
- 115 (1a,5a,6a)-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
116 cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 57)
- 117 (1a,5a,6a)-[3-(2-(3,4-methylenedioxypyphenyl)ethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-  
118 2-hydroxy-2-cyclohexyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 58)
- 119 (1a,5a,6a)-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-  
120 cyclopentyl-2-phenyl acetate. L(+) tartrate salt (Compound No. 59)

- 21 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
22 cyclopentyl-2-phenyl acetamide .hydrochloride salt (Compound No. 60)
- 23 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
24 cyclopentyl-2-phenyl acetamide. L(-) malic acid salt (Compound No. 61)
- 25 (1a,5a,6a)-N-[3-benzyl-3-azabicyclo [3.1.0]-hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
26 cyclopentyl-2-phenyl acetamide. maleate salt (Compound No. 62)
- 27 (2R,2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
28 cyclopentyl-2-phenyl acetamide (Compound No. 63)
- 29 (2R,2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
30 cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound No. 64)
- 31 (2R)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl  
32 2-phenyl acetamide (Compound No. 65)
- 33 (2R)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl  
34 2-phenyl acetamide hydrochloride salt (Compound No. 66)
- 35 (2S)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-  
36 phényl acétamidé (Compound No. 67)
- 37 (2S)-(1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl 2-  
38 phenyl acetamide hydrochloride salt (Compound No. 68)
- 39 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-  
40 cyclopentyl-2-phenyl acetamide (Compound No. 69)
- 41 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
42 cycloheptyl-2-phenyl acetamide (Compound No. 70)
- 43 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
44 cyclobutyl-2-phenyl acetamide (Compound No. 71)
- 45 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
46 cyclobutyl-2-phenyl acetamide tartarate salt (Compound No. 72)

- 147 (2R) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-  
148 difluorocyclopentyl)-2-phenyl acetamide (Compound No. 73)
- 149 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3-  
150 fluorocyclopentyl)-2-phenyl acetamide (Compound No. 74)
- 151 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-  
152 difluorocyclopentyl)-2-phenyl acetamide (Compound No. 75)
- 153 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-  
154 difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound No. 76)
- 155 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-  
156 diphenyl acetate (Compound No. 77)
- 157 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-  
158 diphenyl acetamide (Compound No. 78)
- 159 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
160 cyclohexyl-2-phenyl acetamide (Compound No. 79)
- 161 (2R, 2S) (1a,5a,6a)-N-[3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2- hydroxy-N-  
162 methyl-2-phenyl acetamide (Compound No. 80)
- 163 N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl)  
164 phenylacetamide (Compound No. 81)
- 165 N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl)  
166 phenylacetamide tartarate salt (Compound No. 82)
- 167 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-  
168 phenylacetamide (Compound No. 83)
- 169 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-  
170 phenylacetamide hydrochloride salt (Compound No. 84)
- 171 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-  
172 phenyl acetamide (Compound No. 85)

- 173 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-phenyl acetic acid (Compound No. 86)
- 175 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 87)
- 177 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-cyclopentyl-2-hydroxy-2-(N-methyl) phenylacetamide hydrochloride salt (Compound No. 88)
- 179 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 89)
- 181 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-phenylacetic acid ester (Compound No. 90)
- 183 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(3-pentyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 91)
- 185 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-methyl-2-hydroxy-2-phenylacetamide (Compound No. 92)
- 187 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-isopropyl-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 93)
- 189 (2R, 2S)-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(m-methylphenyl)-2-hydroxy-2-phenylacetic acid ester (Compound No. 94)
- 191 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-phenylacetamide (Compound No. 95)
- 193 (2R, 2S)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-phenylacetamide (Compound No. 96)
- 195 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-fluorophenyl)-2-hydroxy-2-(N-methyl) phenylacetamide (Compound No. 97)

- 197 (2R)-N-[(1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-(p-methylphenyl)-2-hydroxy-2-  
198 (N-methyl) phenylacetamide (Compound No. 98)
- 199 (2R, 2S) (1a, 5a, 6a)-N- {[4-(1,3-dioxo-1, 3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo  
200 [3.1.0] hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 99)
- 201 (2R) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopent-1-  
202 enyl-2-phenylacetamide (Compound No. 100)
- 203 (2R, 2S) (1a, 5a, 6a)-N-(3-Isopropyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
204 cyclopentyl-2-phenylacetamide (Compound No. 101)
- 205 (2R, 2S) (1a, 5a, 6a)-N-(3-Diphenylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
206 cyclopentyl-2-phenylacetamide (Compound No. 102)
- 207 (2R, 2S) (1a, 5a, 6a)-N-(3-sec-butyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
208 cyclopentyl-2-phenylacetamide (Compound No. 103)
- 209 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-  
210 pentyl)-2-phenylacetamide (Compound No. 104)
- 211 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
212 cyclohexyl-2-(4-methoxyphenyl) acetamide (Compound No. 105)
- 213 (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-(N-ethyl)-  
214 2-phenylacetamide (Compound No. 106)
- 215 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
216 cyclopentyl-(N-ethyl)-2-phenylacetamide (Compound No. 107)
- 217 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
218 cyclohexyl-(N-ethyl)-2-phenylacetamide (Compound No. 108)
- 219 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)- 2-hydroxy-2-(3-  
220 pentyl)-(N-methyl)-2-phenylacetamide (Compound No. 109)
- 221 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(sec-  
222 butyl)-(N-methyl)-2-phenylacetamide (Compound No. 110)

- !23 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-(N-methyl)-2-phenylacetamide (Compound No. 111)
- !24 (2R, 2S) (1a, 5a, 6a)-N-[3-(4-tert-butyl-benzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 112)
- !25 (2R, 2S) (1a, 5a, 6a)-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclohex-2-enyl-2-phenylacetamide (Compound No. 113)
- !26 (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 114)
- !27 (2R, 2S) (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 115)
- !28 (2R, 2S) (1a, 5a, 6a)-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 116)
- !29 (1a, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 117)
- !30 (1a, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 118)
- !31 (2R, 2S) (1a, 5a, 6a)-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 119)
- !32 (2R, 2S) (1a, 5a, 6a)-N-[2-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 120)
- !33 (1a, 5a, 6a)-N-[3-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 121)
- !34 (2R, 2S) (1a, 5a, 6a)-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 122)
- !35 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-2-phenylacetamide (Compound No. 123)

90

- :49 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 124)
- :50 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 125)
- :51 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenyl acetic acid ester (Compound No. 126)
- :52 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 127)
- :53 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenylacetamide (Compound No. 128)
- :54 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 129)
- :55 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-methylphenyl)-2-phenyl acetic acid ester (Compound No. 130)
- :56 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-cyclopentyl-2-(3-methylphenyl) acetic acid ester (Compound No. 131)
- :57 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-cyclopentyl-2-(3-methylphenyl) acetic acid ester tartarate salt (Compound No. 132)
- :58 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-cyclopentyl-2-(3-methylphenyl) acetamide (Compound No. 133)
- :59 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-(3-cyclopentyl-2-(3-methylphenyl) acetamide tartarate salt (Compound No. 134)
- :60 (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2,2-di(4-fluorophenyl)acetic acid ester (Compound No. 135)
- :61 (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2,2-di(4-fluorophenyl)-acetamide (Compound No. 136)

- !75 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-cyclobutyl-
- !76 2-phenyl acetic acid ester (Compound No. 137)
- !77 (2R, 2S) (1a, 5a, 6a)-N-(3-cyclohexylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-
- !78 2-cyclopentyl-2-phenylacetamide (Compound No. 138)
- !79 (2R) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-
- !80 (N-methyl)-2-phenylacetamide (Compound No. 139)
- !81 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-
- !82 cyclopentyl-2-(4-methylphenyl) acetamide (Compound No. 140)
- !83 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-phenyl-2-
- !84 (4-methylphenyl) acetic acid ester (Compound No. 141)
- !85 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-2-
- !86 phenyl acetic acid ester (Compound No. 142)
- !87 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-methyl-
- !88 2-phenyl acetamide (Compound No. 143)
- 289 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-isopropyl-
- 290 2-phenyl acetic acid ester (Compound No. 144)
- 291 (1a, 5a, 6a)-N-(3-methyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-phenyl-(N-
- 292 methyl)-2-phenylacetamide (Compound No. 145)
- 293 (1a, 5a, 6a)-N- (3-benzyl-3-azabicyclo [3.1.0] hex-6-yl-methyl]-2-hydroxy-2, 2-di (3-
- 294 methylphenyl) acetamide (Compound No. 146)
- 295 (2R, 2S) (1a, 5a, 6a)-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-hydroxy-2-(3-pentyl)-
- 296 2-phenyl acetic acid ester (Compound No. 147)
- 297 (2R, 2S) (1a, 5a, 6a)-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-methyl-
- 298 (N-methyl)-2-phenylacetamide (Compound No. 148)
- 299 N-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-azabicyclo[3.1.0.]hex-6-yl-methyl]-2-phenyl-2-hydroxy-2-(N-methyl)
- 300 phenyl acetamide hydrochloride (Compound No. 149), or


92

301 Tartarate salt of (3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl cyclopentyl(hydroxy)2-  
 302 thienylacetate (Compound No. 150).

1       3.     A method of treating or preventing autoimmune, inflammatory, or allergic  
 2 disorders, wherein the method comprises administering to a mammal in need thereof a  
 3 pharmaceutical composition comprising one or more muscarinic receptor antagonists  
 4 (“MRA”), and at least one additional active ingredients selected from one or more  $\beta$ 2-  
 5 agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids, anticholinergics,  
 6 dopamine agonists, antiallergics, PAF antagonists, leukotriene antagonists, EGFR kinase  
 7 inhibitors, different muscarinic receptor antagonists or a mixture thereof , wherein the MRA  
 8 has the structures of Formula I, II, or III, wherein

9     a.     Formula I is:

10



Formula I

11

12     or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer,  
 13 diastereomer, N-oxide, polymorphs, prodrugs or metabolite thereof, wherein

14     **Ar**     represents an aryl or a heteroaryl ring having 1-2 heteroatoms independently selected  
 15           from oxygen, sulphur or nitrogen, wherein

16               the aryl or heteroaryl ring may be unsubstituted or substituted by one to three  
 17               substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo  
 18               alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo  
 19               alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>), N-aryl amino,  
 20               amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino carbonyl;


21     **R<sub>1</sub>**     represents hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted amino,  
 22           alkoxy, carbamoyl or halogen (e.g., fluorine, chlorine, bromine and iodine);

23    **R<sub>2</sub>**    represents alkyl, (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl ring, (C<sub>3</sub>-C<sub>7</sub>) cycloalkenyl ring, aryl, heterocyclic  
24    ring, or heteroaryl ring, wherein  
25                the heterocyclic ring or heteroaryl ring may have 1 to 2 heteroatoms  
26                independently selected from oxygen, sulphur or nitrogen, and  
27                the aryl or heteroaryl ring may be unsubstituted or substituted by one to three  
28                substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo  
29                alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower  
30                alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower  
31                alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-aryl amino, amino carbonyl, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or N-  
32                aryl amino carbonyl;  
33    **W**    represents (CH<sub>2</sub>)<sub>p</sub>, wherein p represents 0 to 1;  
34    **X**    represents oxygen, sulphur, -NR or no atom (*i.e.*, a bond), wherein  
35                **R**    represents hydrogen or (C<sub>1</sub>-6) alkyl;  
36    **Y**    represents CHR<sub>5</sub>CO or (CH<sub>2</sub>)<sub>q</sub>, wherein  
37                **R<sub>5</sub>**    represents hydrogen or methyl, and  
38                **q**    represents 0 to 4;  
39    **Z**    represents oxygen, sulphur, or NR<sub>10</sub>, wherein  
40                **R<sub>10</sub>**    represents hydrogen, or C<sub>1</sub>-6 alkyl;  
41    **Q**    represents (CH<sub>2</sub>)<sub>n</sub>, CHR<sub>8</sub> or CH<sub>2</sub>CHR<sub>9</sub>, wherein  
42                **n**    represents 0 to 4,  
43                **R<sub>8</sub>**    represents H, OH, C<sub>1</sub>-6, alkyl, C<sub>1</sub>-6 alkenyl, or C<sub>1</sub>-6 alkoxy, and  
44                **R<sub>9</sub>**    represents H, OH, lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or lower alkoxy (C<sub>1</sub>-C<sub>4</sub>);  
45    **R<sub>6</sub>** and **R<sub>7</sub>** are independently selected from H, CH<sub>3</sub>, COOH, CONH<sub>2</sub>, NH<sub>2</sub> or CH<sub>2</sub>NH<sub>2</sub>; and  
46    **R<sub>4</sub>**    represents hydrogen or C<sub>1</sub>-C<sub>15</sub> saturated or unsaturated aliphatic hydrocarbon group,  
47                wherein  
48                1 to 6 hydrogen atoms of C<sub>1</sub>-C<sub>15</sub> saturated or unsaturated aliphatic hydrocarbon  
49                group may be substituted with a group independently selected from halogen,  
50                arylalkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl, wherein

94

51           heteroarylalkyl or heteroarylalkenyl may have 1 to 2 heteroatoms  
52           independently selected nitrogen, oxygen or sulphur, and  
53           any 1 to 3 hydrogen atoms on the ring of arylalkyl, arylalkenyl,  
54           heteroarylalkenyl may be optionally substituted with lower alkyl ( $C_1-C_4$ ),  
55           lower perhalo alkyl ( $C_1-C_4$ ), cyano, hydroxyl, nitro, lower  
56           alkoxycarbonyl, halogen, lower alkoxy ( $C_1-C_4$ ), lower perhaloalkoxy  
57           ( $C_1-C_4$ ), unsubstituted amino, N-lower alkylamino ( $C_1-C_4$ ), or N-lower  
58           alkylamino carbonyl ( $C_1-C_4$ );

b. Formula II is:



### **Formula II**

60


or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph or metabolite thereof, wherein

**R<sub>1</sub>'** and **R<sub>2</sub>'** are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen; and

**Z'** represents oxygen or NR<sub>3</sub>, wherein

**R<sub>3</sub>** represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

c. Formula III is,



### Formula III

70

95

or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, ester, enantiomer, diastereomer, N-oxide, polymorph, prodrug or metabolite thereof, wherein

**R<sub>1</sub>**" and **R<sub>2</sub>**" are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkenyl or phenyl, wherein phenyl is optionally substituted with one or more groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen;

5 groups independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen;

$\mathbf{R}_3'$  represents C<sub>1</sub>-C<sub>6</sub> alkyl, wherein

1-3 hydrogen atom(s) may be substituted with a group independently selected from C<sub>5</sub>-C<sub>7</sub> cycloalkyl, 1,3-dioxo-1,3-dihydro-isoindolyl or phenyl, wherein

phenyl is optionally substituted with one or more groups independently

10 selected C<sub>1</sub>-C<sub>4</sub> alkyl or halogen; and

**Z** represents oxygen or  $\text{NR}_4^+$ , wherein

$\mathbf{R}_4'$  represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB2006/002930

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61K31/401 A61P11/00 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
**A61K**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2002/052312 A1 (REISS THEODORE F [US] ET AL) 2 May 2002 (2002-05-02) paragraph [0008] claims 1,11	1-3
Y	US 2004/209916 A1 (RICHARDS IVAN MICHAEL [US] ET AL) 21 October 2004 (2004-10-21) claims 1-13	1-3
Y	WO 02/053564 A2 (ALMIRALL PRODESFARMA AG [CH]; PRAT QUINONES MARIA [ES]; FERNANDEZ FORN) 11 July 2002 (2002-07-11) claim 36	1-3
Y	WO 2004/089364 A (RANBAXY LAB LTD [IN]; SALMAN MOHAMMAD [US]; MEHTA ANITA [US]; SARMA PA) 21 October 2004 (2004-10-21) claims 1-5	1-3
	-/-	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

15 January 2007

06/02/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Renard, Delphine

**INTERNATIONAL SEARCH REPORT**

International application No PCT/IB2006/002930
---

**C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2004/005252 A (RANBAXY LAB LTD [IN]; SALMAN MOHAMMAD [IN]; MEHTA ANITA [US]; SARMA PA) 15 January 2004 (2004-01-15) claims 1,6-8 -----	1-3
Y,P	WO 2006/003587 A2 (RANBAXY LAB LTD [IN]; RAO KORLAPATI VENKATESWARA [IN]; KARATGI PRADEEP) 12 January 2006 (2006-01-12) page 1 -----	1-3
Y,P	WO 2006/064304 A (RANBAXY LAB LTD [IN]; SALMAN MOHAMMAD [US]; KUMAR NARESH [IN]; YADAV G) 22 June 2006 (2006-06-22) claims 1-10 -----	1-3
E	WO 2006/117754 A (RANBAXY LAB LTD [IN]; SALMAN MOHAMMAD [US]; KUMAR NARESH [IN]; KAUR KI) 9 November 2006 (2006-11-09) claims 1-5 -----	1-3

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

 International application No  
 PCT/IB2006/002930

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 2002052312	A1	02-05-2002	NONE		
US 2004209916	A1	21-10-2004	NONE		
WO 02053564	A2	11-07-2002	AR 032072 A1		22-10-2003
			AT 334128 T		15-08-2006
			BG 107950 A		31-03-2004
			BR 0116624 A		23-12-2003
			CA 2433128 A1		11-07-2002
			CN 1487938 A		07-04-2004
			CZ 20031812 A3		12-05-2004
			DK 1353919 T3		20-11-2006
			EE 200300312 A		15-10-2003
			EP 1353919 A2		22-10-2003
			HK 1055739 A1		10-11-2006
			HU 0303524 A2		28-01-2004
			JP 2004517123 T		10-06-2004
			MX PA03005862 A		08-09-2005
			NO 20033002 A		30-06-2003
			NZ 526674 A		24-03-2005
			PL 363807 A1		29-11-2004
			RU 2003123120 A		10-01-2005
			SK 7992003 A3		03-08-2004
			UA 75626 C2		15-09-2003
			US 2004072863 A1		15-04-2004
			ZA 200305008 A		08-11-2004
WO 2004089364	A	21-10-2004	AU 2004228452 A1		21-10-2004
			AU 2004228760 A1		21-10-2004
			BR PI0409302 A		11-04-2006
			CA 2521989 A1		21-10-2004
			CA 2522071 A1		21-10-2004
			CN 1795176 A		28-06-2006
			CN 1794985 A		28-06-2006
			EP 1626957 A1		22-02-2006
			WO 2004089900 A1		21-10-2004
			JP 2006522787 T		05-10-2006
			JP 2006522788 T		05-10-2006
WO 2004005252	A	15-01-2004	AT 342253 T		15-11-2006
			AU 2002345266 A1		23-01-2004
			AU 2003226579 A1		23-01-2004
			BR 0215801 A		10-05-2005
			BR 312572 A		10-05-2005
			CA 2491998 A1		15-01-2004
			CA 2492121 A1		15-01-2004
			CN 1668585 A		14-09-2005
			CN 1681784 A		12-10-2005
			EP 1546099 A2		29-06-2005
			EP 1551803 A1		13-07-2005
			WO 2004004629 A2		15-01-2004
			JP 2006502985 T		26-01-2006
			JP 2005535655 T		24-11-2005
			MX PA05000434 A		19-04-2005
			MX PA05000435 A		19-04-2005
			NZ 537585 A		28-07-2006
			US 2006111425 A1		25-05-2006
			US 2007004791 A1		04-01-2007

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No  
PCT/IB2006/002930

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006003587	A2	12-01-2006	NONE
WO 2006064304	A	22-06-2006	NONE
WO 2006117754	A	09-11-2006	NONE